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Myocardial infarction (MI) followed by adverse left ventricular (LV) remodeling is the 
most frequent proximate cause of heart failure (HF). Following MI, neurohormonal 
response is activated and in HF, this activation is sustained and has damaging effects on 
cardiac function. Various microRNAs (miRNAs) have also been identified and linked to 
the development of typical pathological changes of the myocardium after MI. Hydrogen 
sulfide (H2S) is emerging as an important endogenous modulator that exhibits 
cytoprotective effects in diverse physiological and pathophysiological processes. 
However, its role in post-ischemic ventricular remodeling and the associated 
neurohormonal responses, as well as on miRNA profiles has not been well-defined. 
Sodium hydrosulfide (NaHS) as the prototypical H2S donor has been extensively studied, 
however it is highly volatile and might not be physiologically relevant to study the 
therapeutic potential of H2S in vivo. To this end, we utilized a slow-releasing water-
soluble H2S donor, GYY4137 (GYY) that mimics endogenous physiological release of 
H2S. The effect of GYY on LV remodeling and function following myocardial injury has 
not been previously characterized. Therefore, this study was designed to investigate the 
cardioprotective effect of GYY following myocardial injury. We postulated that GYY 
exerts its therapeutic effect by modulating neurohormonal and miRNAs responses to 
cardiac injury. 
 
The results in this thesis demonstrated that GYY treatment, for 2 and 7 days  after acute 
MI in rats, preserved LV dimensions and function in vivo when compared to untreated 
infarcted (MI), placebo- and DL-propargylglycine-  (PAG, an inhibitor of endogenous 
H2S synthesis) treated animals.  LV dimensions and function in GYY-treated animals 
were comparable to healthy sham-operated rats at both time-points. GYY-treated hearts 
viii 
 
had significantly less LV fibrosis than MI, placebo and PAG hearts. In addition, higher 
density of blood vessels was observed in the LV scar area of GYY-treated animals in 
comparison to all other infarcted groups. Despite preserved LV structure and function, 
GYY treatment increased tissue expression and plasma peptide levels of the natriuretic 
peptides, atrial natriuretic peptide (ANP) and b-type natriuretic peptide (BNP), in 
association with enhanced plasma cyclic guanosine 3’5’-cyclic monophosphate (cGMP). 
These results suggest that GYY may exert its therapeutic effects through modulation of 
the natriuretic peptides (NPs)-cGMP pathway.  
 
Furthermore, miR-31 was found to be significantly suppressed upon treatment with GYY 
when compared to MI- and placebo-treated rats at day 7 post-MI. miR-31 has been 
reported to be higher in serum from patients with coronary artery disease (CAD) with 
restenosis when compared to CAD patients without restenosis and to healthy controls. In 
a parallel study, we have found that miR-31 is deleterious to cardiac function and its 
inhibition in vivo prevents the development of HF. Therefore, GYY-mediated modulation 
of miRNAs may contribute to the cardioprotective effect of GYY.  
 
In conclusion, this study has demonstrated that GYY exerted post-ischemic 
cardioprotective effects, which are pro-angiogenic and anti-fibrotic. GYY-mediated 
attenuation of adverse remodeling may be, in part, due to enhanced early post-ischemic 
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1.1    Myocardial infarction  
Myocardial infarction (MI) occurs when a coronary artery supplying nutrients and 
oxygen to the left ventricle is abruptly obstructed leading to an inequality between the 
supply and demand of the heart for oxygenated blood1. MI, complicated by adverse left 
ventricular (LV) remodeling, is the most common proximate cause of heart failure (HF), 
a principal cause of death world-wide2. In Singapore, MI accounted for 16.4% of deaths 
in 20113. The ischemic event leads to the loss of functional cardiomyocytes and impaired 
cardiac contractility, resulting in a sudden increase in loading conditions which in turn 
may trigger a cascade of biochemical intracellular signaling processes leading to LV 
remodeling4. LV remodeling refers to the modifications in shape, size, structure and 
physiology of the cardiac ventricle and is closely connected to the activation of 
circulating neurohormones5. Initially, neurohormonal activation plays an important role 
as part of the compensatory mechanisms following MI6, 7 and the degree of activation is 
associated to the magnitude of the myocardial injury8. This activation comprises 
increased expression of endothelin and cardiac natriuretic peptides (NPs), activation of 
the renin-angiotensin-aldosterone system (RAAS), as well as activation of sympathetic 
nervous system (SNS)9, 10. However, long term neurohormonal activation has potentially 
deleterious consequences on the peripheral circulation and heart leading to further LV 





Figure 1.1 The vicious cycle after MI. Adapted with permission from Elsevier Inc: 
Cardiovascular Pathology 21 (5):365-71, copyright © 201210. 
 
The RAAS is vital in the maintenance of water and electrolyte balance and volume of 
blood. It is stimulated by various stimuli including sympathetic traffic and changes in 
renal perfusion11. Angiotensin 2 (Ang 2), a potent vasoconstrictor, is a product of  renin-
angiotensin activation and chronic elevation of Ang 2 has potentially harmful 
cardiovascular effects12. Ang 2 has been implicated in interstitial cardiac fibrosis by 
promoting fibroblast proliferation and adhesion in addition to extracellular matrix 
proteins synthesis through activation of Ang 2 type I receptor13. It has also been shown 
that Ang 2 receptors expression is up-regulated in hypertrophic cardiomyocytes after MI, 
and stretching of these cells increased Ang 2 production14. Ang 2 also directly triggers 
aldosterone release from the adrenal zona glomerulosa. Aldosterone is the primary 
mineralocorticoid  hormone  regulating systemic salt and water homeostasis15. 
Aldosterone is also involved in the development of myocardial fibrosis and induces 
vascular inflammatory responses16.  
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The NPs, atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are 
released by the heart normally in response to myocardial stretch but also in response to 
ischemia17. They are involved in regulating natriuresis and vasodilation, inhibiting RAAS 
activation and also exerting anti-mitogenic effects on smooth muscle, endothelial, and 
myocardial cells18. Circulating levels of the ANP and BNP are used as predictors in the 
assessment of cardiac dysfunction and failure, and are currently used as diagnostic and  
prognostic tools in the management of patients with cardiac injury including MI18, 19. On 
the other hand, increased levels of the vasoactive peptide endothelin-1 (ET-1) has been 
associated with infarct extension and reduction of coronary blood flow20, 21. Furthermore, 
ET-1 promotes myocardial hypertrophy22. The C-terminal portion of pro-ET-1, which is 
more stable in circulation than ET-1, can also potentially be used as a prognostic marker 
after MI23. In addition, the increase in adrenergic nervous activity has been associated to 
arrhythmias and LV remodeling11. Circulating norepinephrine, the product of  adrenergic 
activation, is toxic to cardiomyocytes24. Antagonism of neurohormonal pathways 
constitutes the mainstay of current pharmacotherapy for cardiac ischemic injury through 
the use of angiotensin converting enzyme (ACE) inhibitors, Ang 2 type 1 receptor 
antagonists (ARBs), blockers of β-adrenoceptors and mineralocorticoid receptor 
antagonists.  
 
1.2    Treatment options after MI 
One of the most effective treatments during MI is reperfusion of the infarcted 
myocardium. Fibrinolytic therapy and primary percutaneous coronary intervention (PCI) 
have been demonstrated to effectively reduce the infarct size, improve LV function and 
decrease mortality of MI patients25, 26. In addition, current pharmacological therapies 
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ameliorate post-MI adverse LV remodeling and suppress the detrimental effects of 
neurohormonal activation (ARBs, β-adrenoceptors blocker therapy, ACE inhibitors, and 
mineralocorticoid receptor antagonist therapy).  
Captopril and enalapril, ACE inhibitors, impair conversion of angiotensin 1 to Ang 2, 
whereas ARBs, such as valsartan and losartan, directly occupy and block Ang 2 type 1 
receptors preventing their activation by Ang 227. Both ACE inhibitors and ARBs decrease 
fibrosis formation in the non-infarcted myocardium and proliferation of fibroblasts 
following MI, which is associated with improved cardiac function and survival28-30. β-
adrenoceptors blocking agents, such as carvedilol and metoprolol, neutralize the harmful 
effects of SNS activation and have been proven clinically to improve LV function after 
MI10, 31. Intravenous treatment of metoprolol in reperfused-ST-segment elevation 
myocardial infarction (STEMI) patients has recently been demonstrated to reduce infarct 
size32. Mineralocorticoid receptor antagonists have also been demonstrated to reduce 
post-MI mortality27, 31.  
Despite the clear benefits of these agents in reducing mortality from 20-30% to 5-10% 
over the last 30 years33, 34, post-MI adverse remodeling remains a common event and 
carries high risk of subsequent HF and mortality35. With the increased immediate survival 
following MI because of percutaneous reperfusion and adjunctive pharmacotherapies 
together with an aging population, we have a growing population having survived acute 
cardiac injury which contributes to the increasing prevalence of HF36, 37. Currently, 
available treatments are insufficient for full prevention of post MI adverse ventricular 
remodeling and the search for new treatment strategies that are more effective in 
protecting the heart against MI, preventing LV remodeling and its subsequent 
cardiovascular events are urgently needed. 
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1.3    Hydrogen sulfide (H2S) as cardioprotectant 
1.3.1 H2S in cardiovascular system 
Hydrogen sulfide (H2S), traditionally recognized as a noxious gas in external 
environmental settings, has now been acknowledged as the third gasotransmitter after 
carbon monoxide and nitric oxide (NO)38, 39. It is highly lipophilic, easily permeable and 
diffusive in the plasma membranes40. Because of its nature, it is difficult to accurately 
measure H2S concentration in blood and tissue. Depending on the method being used, 
H2S in blood and tissue has been reported at concentrations varying between 15nM and 
301µM40. H2S is endogenously generated through enzymatic pathways (i.e. cystathionine 
γ-lyase (CSE), cystathionine β-synthase (CBS), and cysteine aminotransferase (CAT) 
together with mercaptopyruvate sulfurtransferase (3-MST)), non-enzymatic pathways 
(reduction of thiol-containing molecules) and from intracellular sulfane sulfur41-43. The 
key H2S-synthesizing enzyme in the cardiovascular system is CSE44. In recent years, 
various studies have established the involvement of H2S in cell signaling processes43. 
Noteworthy effects of H2S on cell signaling processes, relevant to the cardiovascular 
system, can be divided into four: protein modifications, transcription factors and 
intracellular signaling proteins, ion channels, and metabolism (Figure 1.2)43.   
H2S s-sulfhydrates cellular proteins by adding sulfide to the thiol groups of cysteine 
residues to generate –SSH moiety that may be similar to the s-nitrosylation by NO45. This 
process enhances the biological activity of the s-sulfhydrated GAPDH45. Although the 
effect on other cellular proteins is yet to be investigated, s-sulfhydration could be one of 
the key mechanisms underlying the various effects of H2S on the cardiovascular system. 
H2S also targets various transcription factors, including signal transducer and activator of 
transcription 3 (STAT3) and nuclear factor-E2-related factor 2 (Nrf-2). STAT3 was 
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activated after H2S administration to lipopolysaccharide (LPS)-injected rats46. STAT3 has 
been reported to promote cell survival (through increased survivin), angiogenesis (up-
regulation of vascular endothelial growth factor; VEGF) and proliferation (activation of 
c-fos)47. H2S was found to cause Nrf-2 to localize to the nucleus in ischemic rat hearts48. 
Nuclear Nrf-2 subsequently regulates the expression of heme oxygenase-1 gene and 
thioredoxin-1 gene to limit cardiac injury48. In addition, cardiac Akt and protein kinase C 
(PKC) have been demonstrated to be activated after sodium hydrosulfide (NaHS), a fast-
releasing H2S donor, was briefly infused into isolated hearts of ischemia model. This 
activation resulted in the reduction of myocardial injury and improved cardiac 
mechanical performance49. Other targets of H2S include the ion channels. H2S causes 
vasodilatation via the opening of vascular smooth muscle KATP channels50-53. H2S effects 
on KATP channels also aid in protecting hearts in the ischemia/reperfusion injury model54-
56. Lastly, H2S was also found to suppress oxidative stress in mitochondria by increasing 
intracellular reduced glutathione (GSH) levels57. The antioxidant activity of H2S was 




Figure 1.2 Molecular targets of H2S in cardiovascular system. H2S is known to affect 
(a) protein (cysteine thiol) modifications, (b) intracellular signaling proteins and 
transcription factors, (c) ion channels, and (d) metabolism. Reprinted with permission 
from Li L, et al. Annu Rev Pharmacol Toxicol. 2011; 51:169-87. Copyright © 2011 
Annual Reviews43. 
1.3.2 H2S and MI 
Recent studies have demonstrated that under ischemic conditions, activity of CSE in the 
isolated heart49 and endogenous H2S level in ventricular myocytes44 were reduced. 
Moreover, plasma H2S was decreased in infarcted rats59 and in patients with coronary 
disease60. These observations suggest that impaired endogenous H2S production might 
possibly be involved in the development of MI. In view of this, various groups have 
investigated and demonstrated H2S-mediated cardioprotective effects in MI model in 
vivo. A study done by Zhu and colleagues demonstrated that NaHS, administrated from 7 
days prior to left anterior descending coronary artery (LAD) ligation to 2 days after 
ligation, significantly reduced mortality (~20%) and infarct size (~18%) compared to 
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placebo group61. Similarly, another group reported that treatment with NaHS for 3 days 
after LAD ligation significantly reduced infarct size, prevented LV dilatation and 
preserved the anterior wall thickness compared to placebo group62. The cardioprotective 
effect of H2S treatment post-MI could be explained by several possible mechanisms. One 
study reported that exogenous H2S treatment, after LAD ligation, reduced the infarct size 
and preserved LV function by promoting angiogenesis. Expression of VEGF, a key 
growth factor for angiogenesis, and its receptor (tyrosine kinase receptor and fms-like 
tyrosine kinase) were elevated whereas anti-angiogenic factors such as endostatin, 
angiostatin and parstatin were decreased upon H2S treatment63. Another study implicated 
the involvement of NADPH oxidase 4 (Nox4). Nox4 is one of the important sources of 
reactive oxygen species (ROS) in activated cardiac fibroblast and regulates the 
transcription of pro-fibrotic genes and the redox-dependent pathway64. Administration of 
NaHS decreased activation of Nox4 expression after MI. Reduction of Nox4 was 
complemented with decreased fibrotic response as shown by the reduction of matrix 
metalloproteinase-2 and -9 (MMP-2 and MMP-9) expression level and the activity of 
MMP-2, suggesting that H2S could attenuate LV remodeling after MI through the 
suppression of myocardial fibrosis65. NaHS treatment also exerted its effect via the 
regulation of bcl-2-associated X (BAX)/ B-cell CLL/lymphoma 2 (BCL-2) apoptotic 
signaling pathway. The expression level of BAX, a pro-apoptotic protein, was down-
regulated while BCL-2, an anti-apoptotic protein, was up-regulated upon H2S treatment, 
thus resulting in reduction of caspase-3 activity66. All of these studies demonstrated that 
H2S therapeutic treatment is beneficial to the heart post-MI through the regulation of 




1.3.3 Various H2S donors 
In the initial years, the majority of studies investigating the therapeutic potential of H2S 
utilized commercially available sulfide salts such as NaHS. However, NaHS is highly 
volatile and short-lived. It  releases H2S rapidly in aqueous solution and does not reflect 
the slow and constant H2S synthesis in vivo67. Thus, NaHS might not be a physiologically 
relevant compound to use to study the therapeutic potential of H2S. Because of the 
limitations related to NaHS, researchers have developed novel H2S donors that mimic the 
sustained physiological release of endogenous H2S in vivo. H2S donors that are available 
currently can be grouped as follows.  
1) Naturally occurring H2S donors 
Garlic is a natural organic sulfur-containing plant, derivatives of which have been 
demonstrated to induce H2S release by red blood cells, in the presence of GSH68. Allicin 
(diallyl thiosulfinate) found in garlic is very unstable and decays in water to a number of 
lipid-soluble sulfur-containing molecules such as diallyl sulfide, diallyl disulfide (DADS) 
and diallyl trisulfide (DATS)69. DADS and DATS have been reported to vasodilate rat 
aortae by releasing H2S, suggesting that these compounds could be useful as H2S 
donors68. S-allyl-cysteine (SAC) is a water–soluble component formed in the preparation 
of aged garlic extract70. It can also be generated synthetically from allyl bromide and 
cysteine hydrogen chloride salt70. SAC is the only cysteine analogue that has been 
reported to possibly function as a substrate for H2S production by CSE71. SAC 
significantly increased plasma H2S concentration and could up-regulate expression and 
activity of CSE in the infarcted heart72. These findings suggested that SAC potentially 
acts as an H2S donor. However, there is still no direct evidence on how these natural 
organic sulfur containing compounds may be a source of H2S.    
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2) Synthetic H2S –releasing drugs 
Synthetic H2S-releasing drugs are predominant among H2S donors. Most studies used 
modified existing pharmacological compounds such as NSAIDs (non-steroidal anti-
inflammatory drugs) that contain releasing moiety of H2S, ADT-OH [5-(4-
hydroxyphenyl)-3H-1,2-dithiole-3-thione]). These S-NSAIDs drugs comprise of S-
aspirin, S-diclofenac, S-naproxen, and S-sulindac. S-diclofenac has been demonstrated to 
have better anti-inflammatory effects compared to diclofenac73, 74. It also has the ability to 
inhibit smooth muscle cell proliferation75, and exhibits anti-ischemic58 and anticancer 
properties76. Anti-cancer properties of S-diclofenac and S-sulindac seem to be mediated 
through the inhibition of carcinogen-activating enzymes77. S-NSAIDs have shown 
promising therapeutic potential in cardiovascular diseases and cancers. The reported 
biological effects of these S-NSAIDs, however, could result from ADT-OH moiety itself 
rather than the release of H2S. This is because ADT-OH is biologically active and the 
exact mechanism on how ADT-OH releases H2S has not been fully investigated78, 79. 
Recently, another synthetic H2S-releasing drug, which is not based on structural 
modification of existing drug molecules, has been synthesized and characterized.  This 
compound is covered in the next section.      
          
1.3.4 GYY4137 
GYY4137 (morpholin-4-ium-4-methoxyphenyl (morpholino) phosphinodithioate; Figure 
1.3A), a derivative of Lawesson’s reagent, is a slow-releasing H2S donor that has been 
shown to decompose gradually to generate small quantities of H2S in vitro (Figure 1.3B 
and C) and in vivo (Figure 1.3D and E)53. In their study, Li et al demonstrated that 
NaHS released H2S in vitro rapidly within 5 to 8 seconds (Figure 1.3B) as measured by 
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amperometry, whereas GYY4137 (GYY) released H2S slowly, peaking at around 6-10 
minutes (Figure 1.3C). In vivo, intravenous and intraperitoneal administration of GYY to 
anesthetized rats increased plasma H2S concentration at 30 minutes and it remained 
elevated over the 180-minute time course of the experiment (Figure 1.3D). In contrast, 
administration of NaHS did not increase plasma H2S level at the same time points of 
evaluation (Figure 1.3E). GYY mimics endogenous physiological release and was shown 
to be more effective in relaxing rat aortae compared to NaHS with no toxicity in vitro53. 
In recent years, the beneficial effects of GYY have been reported in several systems. 
GYY has been reported to be protective against endotoxic shock in rat by decreasing 
LPS-induced inflammatory markers in plasma such as tumor necrosis factor alpha (TNF-
α), creatinine, nitrite/nitrate level,  and c-reactive protein, as well as inhibiting activation 
of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) in liver46. It 
also decreased the production of pro-inflammatory mediators from human joint cells in 
vitro80, supporting a possible role of GYY as an anti-inflammatory agent. In addition, 
anti-cancer effects of GYY have been demonstrated in vitro and in vivo81. GYY treatment 
significantly reduced in vitro proliferation of various cancer cell lines. In a mouse 
xenograft model, GYY reduced tumor growth of myelomonocytic leukemia and acute 
promyelocytic leukemia by 52.5% and 55.3% respectively after 14 days, thus confirming 
the anti-cancer effect of this H2S donor. Moreover, GYY relaxed oxytocin-stimulated and 
spontaneous contractions of human myometrial biopsies and pregnant myometrium in 
rat82. In the lung disease model of bronchopulmonary dysplasia, GYY has been reported 
to decrease ROS in hyperoxia-exposed human pulmonary artery endothelial cells, 
enhance capillary-like network formation and also protect mitochondrial function in 
alveolar epithelial cells83. In vivo, GYY treatment attenuated pulmonary artery 





Figure 1.3 GYY4137. (A) Chemical structure of GYY4137. In vitro release rate of H2S 
from (B) NaHS (100 µmol/L) and (C) GYY4137 (1 mmol/L) in phosphate buffer pH 7.4 
as determined by amperometry or spectrophotometrically. Plasma concentration of H2S 
in animals administered with (D) GYY4137 (133 µmol/kg intravenously (i.v) or 
intraperitoneally (i.p) or (E) NaHS (20 µmol/kg i.v). Reprinted with permission from Li 
L, et al. Circulation. 2008; 117:2351-2360. Copyright © 200853. 
 
GYY has significant therapeutic effects in models of cardiovascular disease. Grambow et 
al. demonstrated that GYY prolonged the venular thrombus formation in mice by 
interfering with platelet activation and adhesion molecule-mediated aggregation through 
reduction of circulating soluble P-selectin concentration, suggesting that GYY can 
function as an anti-thrombotic agent84. In addition to its involvement in thrombogenesis, 
GYY also exhibits anti-atherosclerotic activity. GYY treatment in apoE−/− mice fed with 
high-fat diet prevented further aortic atherosclerotic plaque formation and moderately 
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recovered aortic endothelium-dependent vasodilation, most likely through the induction 
of endothelial nitric-oxide synthase (eNOS) phosphorylation85.  In a diabetic myocardial 
injury model, GYY was able to reduce the harmful effects of high glucose treatment in 
rat cardiomyoblast cells as seen from preservation of cell viability and reduction of 
lactate dehydrogenase enzyme activity. This GYY-mediated cytoprotection was 
demonstrated to be the result of AMP-activated protein kinase/mammalian target of 
rapamycin (AMPK/mTOR) signaling pathway activation86. Based on the various 
beneficial effects of GYY, this slow-releasing H2S donor is involved in multiple 
pathways and could be a potential therapeutic agent against adverse post-MI cell loss and 
adverse ventricular remodeling.  
 
1.4    Natriuretic peptides (ANP and BNP) pathway 
ANP and BNP, members of the natriuretic peptide family, are expressed mainly in the 
heart87. Gene expression of ANP is highest in the atria whereas BNP is expressed 
predominantly  in the cardiac ventricles88. proANP is stored in the atrial granules and is 
cleaved into the mature peptide upon release from the atrial granules89. The main 
stimulus for proANP release is atrial stretch caused by increased intravascular volume88. 
Though BNP is also deposited in atrial granules along with ANP90, in the ventricle, BNP 
is not deposited in granules and is constitutively transcribed as required, proportional to 
ventricular myocyte mechanical stretch91. Degradation of ANP and BNP occur through 
the actions of neutral endopeptidase (NEP)92, 93 and by binding to the natriuretic peptide 
clearance receptor (NPR3) 88. Both ANP and BNP bind and activate the transmembrane 
guanylyl cyclase, natriuretic peptide receptor-1 (NPR1) to catalyze the synthesis of the 
intracellular second messenger, cyclic guanosine 3’,5’-monophosphate (cGMP)94. In the 
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cardiovascular system, cGMP exerts its biological action through cGMP-dependent 
protein kinase 1 (cGKI), cGMP-regulated phophodiesterases (PDE2 and PDE3) and 
cGMP-gated cation channels (CNGs)94. The ANP/BNP-cGMP pathway  regulates 
various physiological processes in the cardiovascular system such as fibrosis, 
angiogenesis and cardiac hypertrophy and remodeling95.  
 
1.4.1 ANP/BNP in cardiac hypertrophy and remodeling 
Horio et al. demonstrated that endogenous ANP inhibited cardiomyocyte hypertrophy 
possibly via a cGMP-dependent pathway96. The authors treated cultured cardiomyocytes 
with HS-142-1, a specific antagonist of NPR1, and showed that this antagonist increased 
basal and phenylephrine (PE)-stimulated protein synthesis and enhanced the size of 
myocytes. Treatment with zaprinast, an inhibitor for a cGMP-specific PDE as well as a 
cGMP analogue, attenuated the basal and PE-stimulated protein synthesis. In accordance 
to this observation, animal studies with a modified ANP/BNP-cGMP pathway have 
shown similar results. Mice with cardiac-restricted NPR1 deletion displayed minor 
cardiac hypertrophy, accompanied by an increase in circulating ANP level and gene 
expression of cardiac hypertrophy markers including skeletal-actin, ANP, and alpha-
myosin heavy chain97. Furthermore, these transgenic mice developed enhanced cardiac 
hypertrophy and marked deterioration of cardiac function in response to aortic 
constriction. In contrast, mice with cardiac overexpression of NPR1 displayed reduction 
in cardiomyocyte size and ANP mRNA expression98. Moreover, cardiac overexpression 
of constitutive active guanylyl cylase (GC) prevented pressure-overload-derived 
hypertrophy in a mouse model99. Taken together, these observations suggest the ANP and 
BNP/NPR1/cGMP system is anti-hypertrophic.    
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1.4.2 ANP/BNP modulation of fibroblasts 
Natriuretic peptide receptors are expressed in cardiac fibroblasts, as well as 
cardiomyocytes100. However, in contrast to cardiomyocytes that express predominantly 
NPR1, cardiac fibroblasts express both NPR1 and natriuretic peptide receptor-2 (NPR2). 
ANP and BNP treatment of cultured cardiac fibroblasts increased cGMP and inhibited 
Ang 2-induced DNA synthesis101. Furthermore, myocyte-conditioned medium and 
exogenous application of ANP inhibit collagen synthesis in cardiac fibroblasts, while 
treatment with HS-142-1, a specific antagonist of NPR1, reverses this effect102. These 
observations suggest that ANP and BNP generated by myocytes could suppress cardiac 
fibroblast proliferation through paracrine effects; this concept is further reinforced by a 
recent animal study. In response to aortic constriction, ANP knock-out mice developed 
robust cardiac interstitial and perivascular fibrosis with collagen deposition103. Mice 
lacking BNP exhibited multifocal ventricular fibrotic lesions in response to abdominal 
aortic constriction104. These findings demonstrated the anti-fibrotic effects of ANP and 
BNP.  
 
1.4.3 ANP/BNP modulation of angiogenesis 
Evidences suggest that the ANP/BNP-cGMP pathway is involved in promoting 
angiogenesis in ischemic tissues. Exogenous application of ANP increased cGMP level in 
human umbilical vein endothelial cells and promoted endothelial tube formation105. 
Likewise, BNP stimulated migration and proliferation of cultured microvascular 
endothelial cells106.  In vivo study of the hind-limb ischemia mice model demonstrated 
that systemic BNP injection significantly improved blood flow and capillary density107.  
Yamahara et al. also reported that transgenic mice, overexpressing BNP had enhanced 
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neovascularization in the hind-limb ischemia model108. Vascular remodeling was 
significantly impaired in NPR1 knock-out mice in response to limb ischemia106, 109. 
Furthermore, a significant association between circulating N-terminal proBNP level and 
endothelial progenitor cells (EPCs) colony forming unit in HF patients has been 
reported107, supporting the involvement of ANP/BNP in angiogenesis.  
 
1.4.4 Clinical application of ANP/BNP  
Preclinical studies in patients with congestive HF have reported that infusion of ANP 
improved cardiac function by regulating loading conditions for LV110-112. Since then, the 
use of recombinant ANP (carperitide) to treat acute MI has been approved in Japan 
whereas recombinant BNP (nesiritide) is approved by the Food and Drug Administration 
(FDA), USA for treatment of acute decompensated heart failure (ADHF)113. Hayashi et 
al. demonstrated that infusion of carperitide to 30 patients with acute myocardial 
infarction (AMI) after coronary intervention improved LV remodeling as indicated by 
significantly higher ejection fraction (EF) when compared to control group114. In a bigger 
study, Kitakaze et al. reported that infarct size was significantly reduced by 15% and EF 
was markedly higher in the carperitide group relative to placebo group115. Both studies 
demonstrated that treatment with ANP is beneficial as an adjunct therapy in patients with 
AMI. However, further studies are needed to address the controversy surrounding the 




1.5 microRNAs (miRNAs) 
MicroRNAs (miRNAs), short non-coding RNA molecules of 20-22 nucleotides length, 
have been recognized as physiological regulators of gene expression through translational 
repression or degradation of messenger RNAs (mRNAs) by binding to the target 
sequences in the 3’ untranslated region (3’UTR) of mRNAs116, 117. The expression of 
miRNAs has been shown to be closely regulated and is specific to different organs and 
cell types118. In recent years, various miRNAs have been identified and recognized as 
playing a role in the pathophysiology of many diseases including cancers and 
cardiovascular diseases119, 120. The emerging interest in miRNAs stems from their two 
potential clinical applications. Firstly, it is known that many diseases are characterized by 
abnormal miRNAs expression. As such, comparison of miRNA profiles between normal 
and diseased samples allows for the identification of crucial miRNAs that are changed 
during the development of pathological conditions. Identification of these dysregulated 
miRNAs in the circulation might potentially render miRNAs useful as early disease 
biomarkers. The second application is the therapeutic targeting of miRNAs that are 
linked to pathways related to the disease pathophysiology. In the cardiovascular field, 
specific miRNAs have been found to be related to the progression of typical pathological 
changes of the heart after MI which include induction of apoptosis (miR-1 and miR-
206)121, arrhythmia (miR-1)122, neo-angiogenesis (miR-92a and miR-210)123, 124, cardiac 
fibrosis (miR-21 and miR-101)125, 126 and inflammatory response (miR-223 and miR-
29)127, 128. These associations suggest that miRNAs could be useful as new diagnostic and 
prognostic markers of MI and therapeutic targets in treatment or prevention of post-MI 
remodeling. Moreover, plasma levels of specific miRNAs (miR-1, miR-208a, miR-133, 




1.6 Hypotheses and study aims 
The effect of the slow releasing-H2S donor, GYY, has never been evaluated in the 
myocardial infarction model and the relationship of GYY with neurohormonal 
modulation and miRNA profiles have not been well-defined. Hence, we hypothesized 
that GYY is cardioprotective against myocardial infarction and exerts its effect, in part, 
through modulation of the neurohormonal response and miRNAs. 
The specific aims of this study are: 
1. To assess the effects of GYY with respect to cardiac function and structure, as 
well as its therapeutic effects in the early and late post-MI period in a rat model 
of myocardial infarction. 
2. To investigate the relationship of observed potential therapeutic effects of GYY 
with neurohormonal response upon ischemic cardiac injury. 
3. To explore the effect of post ischemic GYY treatment on miRNAs profiles in the 













2. MATERIALS AND METHODS 
2.1 Experimental design 
Overview of the experimental design could be seen in Figure 2.1. Male wistar rats 
underwent baseline echocardiography were distributed randomly to sham/healthy control 
group or disease groups. Rats in disease groups underwent LAD coronary artery ligation 
and were assigned randomly to untreated (MI) group and treated groups: including 
placebo (injected with 0.9% saline solution), GYY (treated with GYY4137) and PAG 
(treated with DL-propargylglycine (PAG)) 30 minutes (min) after LAD ligation. At each 
of two time-points (2 days and 7 days), final echocardiography and hemodynamic 
measurement were performed. Tissues and blood were collected for further analyses. 
 
Figure 2.1 Schematic of the experimental design of the study. 
LAD, left anterior descending coronary artery; MI, infarcted untreated; Placebo, infarcted placebo-
treated group; GYY, infarcted GYY-treated group; PAG, infarcted PAG-treated group; SSN, 
saline; IP, intra peritoneal; QPCR, quantitative real-time polymerase chain reaction; mRNA, 
messenger RNA; miRNAs, microRNAs; IHC, immunohistochemistry; WB, western blot; cGMP, 
Guanosine 3’5’-cyclic monophosphate; NO, nitric oxide. 
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2.2 Treatment drugs 
2.2.1 H2S donor 
The slow releasing-H2S donor, GYY, used in this project was synthesized in-house by the 
Department of Pharmacology and Department of Chemistry, National University of 
Singapore. For intra peritoneal (IP) injection, appropriate dosage (100mg/kg) was 
aliquoted and diluted in 1.5ml of 0.9% saline. In order to completely dissolve GYY, 
solution was then sonicated for 10 seconds (sec) and repeated for three times with 5sec 
interval on ice (sonicator XL-2000 series; QSonica LLC, CT, USA). Next, solution was 
passed through 0.2µm syringe filter (Sartorius AG, Goettingen, Germany) inside the 
biological safety cabinet and loaded into sterile 3ml syringe for IP injection. 
 
2.2.2 Cystathionine γ-lyase (CSE) antagonist 
PAG, a CSE antagonist (Sigma Aldrich, St. Louis, MO, USA) was used at a dosage of 
50mg/kg. It was diluted in 1.5ml of 0.9% saline for IP injection. Solution was passed 
through 0.2µm-syringe filter (Sartorius AG, Goettingen, Germany) inside the biological 
safety cabinet and loaded into sterile 3ml syringe for IP injection. 
 
2.3 Rat model of myocardial infarction  
All animal experiments were consented by the Institutional Animal Care and Use 
Committee (IACUC) of the National University of Singapore and performed in 
accordance to the established guiding principles for animal research. Eighty-four male 
Wistar Rats ((250-300g); NUS Care) were used in this study. Anesthesia was induced and 
maintained with inhalational isoflurane (2%; Baxter, Deerfield, IL, USA). Rats were 
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intubated with 16G catheter (Terumo Corporation, Tokyo, Japan) attached to the 
ventilator (Harvard Apparatus, MA, USA) throughout the procedure. The heart was 
exposed by fourth intercostal space incision (left-thoracotomy) and pericardium incision 
(pericardectomy). A myocardial infarction was created with an LAD ligation, which was 
performed by inserting a 7-0 polypropylene suture stitch (B.Braun, Germany) from the 
left border of the pulmonary conus to the right border of the left atrial appendage. An 
acute myocardial infarction was evaluated by immediate observation of myocardial 
blanching and ST segment changes in electrocardiogram. After the procedure, the chest 
was closed in three layers as follows: ribs and muscle were closed with 5-0 absorbable 
glyconate suture and skin was closed with 5-0 polypropylene suture (B.Braun, Germany).  
Animals that only underwent lateral thoracotomy and pericardectomy were used as sham 
healthy controls. Animals were randomly assigned to receive therapeutic treatment 30min 
after ligation and were allowed to recover in a small-animal intensive care unit. 
Treatments were followed for 2 days and 7 days in rats that survived the first 24 hours 
(hr) after LAD ligation as follows for each time point (Figure 2.1): healthy sham-
operated (n=6), untreated myocardial infarction (MI; n=9), placebo (infarcted injected 
with 0.9% saline solution, 1.5ml/24hr IP; n=9), GYY (infarcted treated with GYY4137, 
100mg/kg/48hr IP; n=9) and PAG (infarcted treated with PAG, 50mg/kg/24hr IP; n=9). 
The dose of GYY used in this study was based upon prior studies of effective doses of 
this compound in other animal models46, 85. Animals received Carprofen (5mg/kg, once 
daily, subcutaneous (SC)) and Enrofloxacin (25mg/kg, twice daily, SC) postoperatively 




Transthoracic echocardiography was carried out in all animals at baseline (before 
surgery) and on the same day of euthanasia at day 2 and day 7 post-MI using Vivid 7 
Dimension ultrasound system equipped with a broadband 10S transducer (GE VingMed, 
Horten, Norway). Rats were induced and maintained with inhalational isoflurane (2%; 
Baxter) during the procedure. LV wall thickness and internal diameter during diastole 
and systole were obtained from M-mode recordings of the LV in the para-stemal short-
axis view. LV end diastolic diameter (LVEDD) and LV end systolic diameter (LVESD) 
were obtained from M-mode recordings. LV volumes were calculated using a modified 
Teichholz formula where LV end diastolic volume was calculated as LVEDV= [(π x (LV 
diastolic internal diameter)3)/(6 x (ellipticity factor of ⅓)] and LV end systolic volume 
was calculated as LVESV=[(π x  (LV systolic internal diameter)3)/(6 x (ellipticity factor 
of ⅓)]. LV fractional shortening (%FS) was calculated as [(LVEDD- LVESD)/LVEDD] 
x 100. LV ejection fraction (%EF) was calculated as [(LVESV - LVEDV)/LVEDV] x 
100. Offline measurements of LV dimensions and areas were made from three 
consecutive cardiac cycles using EchoPac software (version 6; GE VingMed, Horten, 
Norway). 
 
2.5 Hemodynamic measurements 
Assessment of LV pressure and volume were carried out 2 days and 7 days post-
treatment. Animals were induced and maintained with inhalational isoflurane (3%; 
Baxter) during the procedure. Similar to the myocardial injury procedure, animals were 
intubated with 16G catheter attached to ventilator (Harvard Apparatus). Mid-thoracotomy 
was done to expose the heart and the ascending aorta. A 2-mm transient-time flow probe 
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was positioned around of the ascending aorta for cardiac output (CO) measurement 
(Transonic Systems, Inc, Ithaca, NY, USA). Subsequently, a pressure transducer catheter 
(Millar Micro-Tip® model SPR-838; Millar, Inc, TX, USA) was inserted to the apex of 
LV. Aortic flow and pressure waves were recorded with the Powerlab 8/30 data 
acquisition system (ADInstruments Pte Ltd, Castle Hill, NSW, Australia). Data were 
analyzed with Lab Chart Pro software (version 7.0; ADInstruments). 
 
2.6 Tissues and blood collection 
Following hemodynamic measurements, terminal injection of pentobarbitone (150mg/kg, 
IP) was injected. Five ml of blood was collected in 7.2mg EDTA tube through cardiac 
puncture. Plasma was obtained by blood centrifugation (3,000g for 5 min, at 4°C) and 
stored at -80°C until processing for biochemical assays. The heart was excised and 
perfused with ice cold 1 x Phosphate Buffered Saline (1st Base, Singapore) to remove 
excess blood. Perfused heart was then cut into 2 cross sections. The upper slice was 
further halved and fixed in 10% formalin (Sigma Aldrich, St. Louis, MO, USA) for 
histology.  Tissue from the lower portion encompassing infarct and peri-infarct areas (or 
the corresponding antero-inferior left ventricular region in sham animals) was divided 
equally for RNA and protein extraction, and immediately flash-frozen in liquid nitrogen. 
The liver was excised and immediately flash-frozen in liquid nitrogen. Tissues were 
stored at -80°C until further processing.      
 
2.7 Histology for LV infarct size  
One of the upper-halved formalin-fixed heart slices was embedded in paraffin. Paraffin-
embedded heart tissue was then cut into 5μm sections, and then stained for Masson’s 
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trichrome as follows. Paraffin-embedded heart tissue was de-paraffinized and rehydrated 
by washing the tissue section twice with xylene at 5min each, followed by twice 100% 
ethanol rinses (5min each), followed by 95% ethanol (5min), 70% ethanol (5min), 50% 
ethanol (5min), 30% ethanol (5min) and finally washed with water. Tissue section was 
then stained with weigert’s iron hematoxylin working solution for 10min (Sigma Aldrich, 
St. Louis, MO, USA) followed by rinsing in running warm tap water for 10min and 
washing with water. Next, tissue section was stained with biebrich scarlet-acid fuchsin 
solutions (Sigma Aldrich, St. Louis, MO, USA) for 15min and washed with water 
followed by incubation in phosphomolybdic-phophotungstic acid solution (Sigma 
Aldrich, St. Louis, MO, USA) for 10min. Without rinsing, tissue section was then stained 
with aniline blue solution (Sigma Aldrich, St. Louis, MO, USA) for 5min, rinsed with 
water and incubated in 1% acetic acid solution (Sigma Aldrich, St. Louis, MO, USA) for 
2 min. Following washing in water, tissue section was dehydrated through 95% ethanol 
(2min), 100% ethanol (2min) and xylene (2min). Then, tissue sections were mounted 
with resin mounting medium (Sigma Aldrich, St. Louis, MO, USA). Collagen fibers were 
stained green and represented the infarcted area whereas viable muscle cells were stained 
red. For infarct size determination, Masson’s trichrome-stained heart cross sections were 
imaged using a Nikon Eclipse Ti microscope (4x objective; Nikon, Tokyo, Japan) and the 
whole heart cross sections’ image was obtained using NIS-Elements AR 3.2 software 
(Nikon, Tokyo, Japan). Subsequently, the percentage of the scarred LV wall was 
determined using the area measurement (calculated by dividing the infarcted area by the 





The second upper-halved formalin-fixed heart slices were then cryoprotected in 20% 
sucrose at 4°C overnight. The cryoprotected heart was then embedded in OCT (optimal 
cutting temperature; Sakura Finetek, CA, USA) and stored at -80°C overnight prior to 
cryosection. OCT-embedded heart tissue was then cut into 10μm sections and subjected 
to immunohistochemistry with procedures as follows. Tissue sections on the slides were 
allowed to air-dry inside the fume hood for 15min. PAP pen (LifeTechnologies, 
Carlsbad, CA, USA) was used to demarcate the area surrounding the tissue sections. 
Tissue sections were then re-fixed in cold 10% formalin for 15min and then air-dried for 
another 15min. Subsequently, tissue sections were re-hydrated in 1x Tris Buffered Saline 
(TBS; 1st Base) for 5min followed by incubation in blocking solution (5% goat serum, 
0.5% triton-X 100, 5% bovine serum albumin (BSA) in 1x TBS) for 30min. Following 
blocking, tissue sections were incubated with antibody against rat endothelial cells (1:50 
mouse monoclonal anti-RECA-1; Hycult biotechnology, Uden, The Netherlands) for 2hr 
at room temperature (r.t). Tissue sections were then washed three times with 1x TBS at 
5min each followed by secondary antibody incubation (goat anti mouse Alexa Fluor-594; 
LifeTechnologies, Carlsbad, CA, USA) for 1hr at r.t. Next, after repeated washing, 
sections were incubated with anti-actin-α-smooth muscle (SMA) (FITC conjugated, 
1:500, mouse monoclonal clone 1A4, Sigma Aldrich, MO, USA) for 1.5hr at r.t. 
Following three times wash, tissue sections were mounted with prolong gold with DAPI 
(LifeTechnologies, Carlsbad, CA, USA) to stain the nuclei and kept at 4°C until imaging. 
Tissue sections were imaged using Nikon Eclipse Ti microscope (Nikon Instruments Inc, 
Melville, NY, USA) and captured using NIS-Elements AR 3.2 software. Images from 10 
random high power fields per LV infarct zone (200x) were taken from four animals per 
infarcted group per time point. Quantifications of RECA-1 positive and SMA positive 
26 
 
blood vessels were done using ImageJ software (1.42q, National Institutes of Health, 
Bethesda, MD, USA). 
 
2.9 Plasma H2S measurement 
Plasma H2S was measured by a high-performance liquid chromatography (HPLC) 
method using monobromobimane (MBB). Rat plasma samples (15μl) and NaHS 
standards were derivatized with fluorescent probe MBB (2mM) for 30min at r.t in 
hypoxic chamber (1% O2) in the dark to form sulfide-dibimane. Excess MBB was 
quenched by addition of 2-mercaptoethanol. Mixture was extracted with ethyl acetate. 
Organic layer was transferred into a fresh 50ml tube, evaporated under nitrogen steam 
and dissolved in water and methanol mixture (10:90). Derivatized NaHS stock solution 
was used to prepare a standard curve of NaHS (0.018–1.5µM). HPLC analysis of 
derivatized rat plasma and NaHS solution was performed on a C18 column using an 
Agilent 1100 Series HPLC System (Santa Clara, California, USA) with mobile phases 
comprising of 10% v/v methanol and 0.25% v/v acetic acid and 90% v/v methanol and 
0.25% v/v acetic acid. Excitation and emission wavelengths were 385 nm and 475 nm 
respectively. Retention time of the derivatized H2S in this system was 24.4 ± 0.01min. 
Concentration of the H2S in the rat plasma was measured from linear plots of the HPLC 
peak areas of sulfide-dibimane versus known concentration of NaHS solution. 
 
2.10 Measurement of tissue H2S synthesizing enzyme activity 
Tissue H2S synthesizing enzyme activity was determined as follows. Liver tissue from 
placebo-treated and PAG-treated rats obtained 2 and 7 days after myocardial infarction 
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(n=6/group/time-point) was homogenized (1:30 v/v) in ice-cold potassium phosphate 
buffer (100mM, pH 7.4). The assay mixture (500µl) containing tissue homogenate 
(430µl), L-cysteine (10mM; 20µl), pyridoxal 5’-phosphate (2mM; 20µl) (Sigma Aldrich, 
MO, USA), and saline solution (30µl) was incubated at 37°C for 30 min in parafilm-
sealed microcentrifuge tubes.  Next, zinc acetate (1% w/v, 250µl) was added to trap H2S 
followed by addition of trichloroacetic acid (10% w/v, 250µl) to halt the reaction. 
Subsequently, N,N-dimethyl-p-phenylenediamine sulfate (20mM; 133µl) in 7.2M HCl 
was added followed immediately by FeCl3 (30µM; 133µl) in 1.2M HCl. All standards 
and samples were assayed in duplicate and absorbance (670 nm) was read using a 96-well 
microplate reader (Tecan Systems Inc., USA). The concentration of H2S in each sample 
was calculated from the standard curve of sodium hydrosulfide (NaHS, 
3.125−250µmol/L). Results are presented as nanomoles of H2S generated per milligram 
soluble protein. Soluble protein concentration was determined using Bradford assay 
(BioRad Laboratories, Herculer, CA, USA). 
 
2.11 Plasma neurohormones assays 
2.11.1 Plasma renin activity assays 
Plasma renin activity assay was done according to an established method. The 
angiotensinase inhibitors- dimercaprol and 8-hydroxyquinoline and incubation buffer (pH 
7.4) were added to the plasma samples and incubated at 37°C for 3hr. Identical control 
incubation at 4°C was also carried out on each plasma sample. Reaction of renin on its 
endogenous substrate angiotensinogen produced angiotensin 1 in these samples and the 
level of angiotensin 1 was measured by radioimmunoassay as follows. Incubated plasma 
(25μl) or Angiotensin 1 standard, [125I] Angiotensin 1 (50μL) and Angiotensin 1 specific 
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antiserum (50μl) were incubated for 24hr at 4°C. Bound and free radio labelled 
Angiotensin 1 was separated by addition of solid phase second antibody method in which 
0.5ml of 5% Sac-Cel (Immunodiagnostic Systems, Boldon, UK) plus 5% Dextran (Sigma 
Aldrich, St. Louis, MO, USA) in assay buffer was added, vortexed, stood at r.t. for 30 
min and then centrifuged at 2,000g for 15min at 20°C. Bound labelled Angiotensin 1 was 
pelleted and counted in a Gammamaster gammacounter (LKB, Uppsala, Sweden). Using 
the standard curve, the amount of Angiotensin 1 in each sample was calculated and the 
net amount generated over the 3hr incubation was obtained by subtraction of the 
endogenous Angiotensin 1 that was measured in the identical control incubations. Plasma 
renin activity referred to nanomol Angiotensin 1 produced/liter of plasma/hour). 
 
2.11.2 Endothelin assay 
Endothelin was firstly iodinated by a Lactoperoxidase method as follows. 7.5μg 
Endothelin-1 and 25μl 0.4M Sodium Acetate buffer were reacted with 18MBq of Na125I 
(Amersham – UK), 20μg Lactoperoxidase and 100ng H2O2 for 10min followed by 
addition of another 100 ng H2O2 for an additional 10 min incubation. Next, the solution 
was separated using a gradient of 20-100% acetonitrile in 49mM phosphate buffer pH 2.9 
for 40min on a 10cm Brownlee Aquapore RP300 7micron HPLC column. Monoiodinated 
endothelin was eluted, purified and used as a tracer. For radioimmunoassay, endothelin 
was extracted from plasma by C18 SepPak cartridges (Waters Associates, Millford, MA, 
USA), washed with 5mL methanol followed by 5mL of 0.1% trifluroacetic acid (TFA). 
Endothelin was then eluted from plasma with 2ml of 80% isopropanol in 0.1% TFA, 
dried at 37°C, and dissolved in assay buffer (0.5ml of 0.1M phosphate buffer (pH 7.4), 
0.05M NaCl, 0.1% BSA, 0.1% Triton x-100 and 0.01% NaN3). Endothelin was assessed 
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by adding 50μl of standard or plasma samples with 50μl of endothelin antiserum (cat. 
number RAS6901, Bachem, Torrance, CA, USA). The assay was incubated at 4°C for 
22-24hr, followed by addition of 50μl of tracer 125I labelled endothelin (2,000-2,500 cpm) 
and then incubated at 4°C for another 22-24hr. Bound and free endothelin were separated 
using a solid phase second antibody method (refer to section 2.11.1). After removal of 
supernatant, the pellet was then counted in a Gammamaster gammacounter (LKB, 
Uppsala, Sweden). Using the standard curve, the amount of endothelin in each sample 
was calculated. 
 
2.11.3 ANP assay 
ANP was extracted from plasma by C18 SepPak cartridges (Waters Associates, Millford, 
MA, USA) similar to endothelin assay, and then subjected to radioimmunoassay as 
follows. 100µl of radioactively labelled human ANP was allowed to react with 100µl of 
ANP antibody in the presence of varying amounts of rat ANP-28, standard or plasma 
extracts. The assay was incubated for 22-24hr at 4ºC. The amount of ANP in the plasma 
extract was estimated by evaluating the extent of binding of the labelled ANP to the 
antibody. After incubation, bound and free radiolabelled ANP was separated using a solid 
phase second antibody method (refer to section 2.11.1) and centrifuged to precipitate the 
bound radiolabelled ANP. The bound ANP was counted using a Gammamaster 
gammacounter (LKB, Uppsala, Sweden) to generate dose response curve of radioactivity 
versus peptide concentration from which the ANP concentration in plasma extracts and 




2.11.4 BNP assay 
BNP assay was determined with competitive binding assay ratBNP enzyme immunoassay 
kit (Phoenix Pharmaceuticals, Inc, Burlingame, CA, USA) in accordance to the 
manufacturer’s protocol as follows. Firstly, peptide was extracted from plasma samples 
using C18 Sep-column and the extracted peptide was dried and reconstituted in 1x assay 
buffer. The plate used in this kit was pre-coated with secondary antibody and the 
nonspecific binding sites were blocked. 50µl of extracted peptide from plasma samples, 
50µl of standard (0.01ng/ml-100ng/ml), 50µl of positive controls was added to the 
respective well. Then, 25µl of anti-BNP antibody and 25µl of biotinylated BNP was 
added to each well and incubated for 2hr at r.t with orbital shaking at 300-400rpm. . At 
the end of incubation, solution was decanted and plate was washed for 4 times with 1x 
assay buffer. Subsequently, 100µl of streptavidin-horseradish peroxidase (SA-HRP) was 
added and incubated for 1hr at r.t with orbital shaking at 300-400rpm. Plate was then 
washed again for 4 times with 1x assay buffer. 100µl of 3.3’5,5’-tetramethylbenzidinee 
(TMB) substrate solution was then added and incubated for 1 hour at r.t with orbital 
shaking 300-400rpm protected from light. Finally, 100µl of 2N HCl was added to the 
well to halt the reaction. The colour of the solution would change from blue to yellow 
and the absorbance was read at 450nm. The intensity of the change in color (yellow) 
generated was directly proportional to the total of biotinylated peptide-SA-HRP complex 
but inversely proportional to the amount of the peptide in standard solutions or plasma 
samples. This was due to the competitive binding of the biotinylated peptide with the 
standard peptide or samples to the BNP antibody. A standard curve of known 
concentration of standard peptide was established and the unknown concentration in 




2.11.5 Aldosterone assay 
Aldosterone was measured by direct radioimmunoassay. Aldosterone standard in 100l 
of charcoal stripped plasma, or 100l of plasma sample were mixed with aldosterone 
antiserum and [1251] aldosterone-3-carboxymethyl oxime in 400l of assay buffer  (citrate 
68 mmol/L and phosphate 64 mmol/L, containing 2 g of BSA/L; pH 3.6) and incubated 
for 24hr at 4°C. The assay was separated by addition of dextran coated charcoal solution 
followed by centrifugation. Supernatant was then decanted and the charcoal pellet was 
counted using a Gammamaster gammacounter (LKB, Uppsala, Sweden). Standard curve 
was generated from the aldosterone standard and the amount of aldosterone in plasma 
was then calculated from the curve. 
 
2.12 Plasma cGMP measurement 
Guanosine 3’5’-cyclic monophosphate (cyclic GMP; cGMP) was measured using the 
cyclic GMP complete Enzyme-Linked Immunosorbent Assay (ELISA) kit (Enzo Life 
Sciences Inc., NY, USA) with the acetylated format to increase the sensitivity according 
to the manufacturer’s protocol as described below. 
 
2.12.1 Sample preparation 
Plasma samples were directly used for the assay. Standards for plasma samples were 
diluted in assay buffer 2 to concentrations of 50, 10, 2, 0.4 and 0.08 pmol/ml. All 
standards and samples were acetylated by adding 10μl of the acetylating reagent for each 
200μl of the standard or sample. 
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2.12.2 Assay Procedure 
Neutralizing reagent was added first to each well of goat anti-rabbit antibody-coated plate 
when measuring cGMP from tissue samples but not for plasma samples. Next, 100μl of 
standards and samples were added to the appropriate wells followed by 50μl of cGMP 
conjugate and 50μl of cGMP antibody. Plate was sealed and incubated for 2hr on a plate 
shaker (500rpm) at r.t. After that, contents of the wells were removed and wells were 
washed with 400μl of wash buffer repeated for a total of 3 washes. Wash buffer was 
completely aspirated and 200μl of substrate solution was added to each well. Plate was 
incubated for 1hr at r.t without shaking. Finally, reaction was stopped by adding 50μl of 
stop solution and the absorbance readout at 405nm was obtained using Enspire 2300 
multilable reader (Perkin Elmer, MA, USA). A standard curve was generated using non-
linear logistic regression analysis with 4 parameters (4-PL). The cGMP level was 
calculated using the cGMP standard curve after subtraction of the background reading 
(substrate blank). Level of cGMP was expressed as picomole per ml (pmol/ml). 
 
2.13 Plasma nitric oxide measurement 
Plasma samples were purified by passing them through a 10kDa molecular weight cut-off 
centrifugal filter (Merck Millipore, Danstadt, Germany) to remove high molecular weight 
proteins that may confound the result. Nitric Oxide metabolites were measured using 
nitric oxide fluorometric assay kit (BioVision Inc., Milpitas, CA, USA) according to the 
manufacturer’s protocol as follows. After filtration, 75μl of sample was combined with 
5μl of 1mM enzyme cofactor and 5μl of nitrate reductase. Sample was incubated at r.t. 
for 4hr to allow 99% conversion of nitrate into nitrite. Then, 5μl of enhancer was added 
and incubated for 30min at r.t. to quench interfering compounds. 5μl of DAN reagent (2, 
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3-diaminonaphthalene) was added and incubated for 10min at r.t. to allow reaction with 
nitrite. Finally, 5μl of NaOH was added and incubated for 10min at r.t to enhance the 
fluorescent yield. Fluorescent intensity reading at excitation wavelength of 360nm and 
emission wavelength at 450nm was obtained by Enspire 2300 multilable reader (Perkin 
Elmer, MA, USA). Standard curve was obtained using nitrate/nitrite standards. Total 
nitrate/nitrite concentration (μM) was calculated as C = [nitrate+nitrite] (μM) = 
[(fluorescence – y intercept/slope)/sample volume (μl)] x dilution factor. 
 
2.14 RNA extraction and quality control 
2.14.1 Total RNA isolation 
Total RNA was isolated using TRIzol (Life Technologies, Carlsbad, CA, USA) method 
according to the manufacturer’s protocol as follows. Firstly, heart tissue from the infarct 
and peri-infarct area was ground into a fine powder using pestle and mortar under liquid 
nitrogen to prevent degradation. 1ml of TRIzol (per heart tissue sample) was added and 
transferred to microcentrifuge tube, resuspended and incubated for 10min at r.t. 
Resuspended sample was then subjected to phase separation by adding 200μl of 
chloroform and shaken vigorously for 30sec, followed by 3min incubation at r.t. After 
incubation, mixed suspension was then subjected to 13,000rpm centrifugation for 15min 
at 4°C. Three separate layers can be observed after centrifugation. The uppermost 
aqueous transparent phase was then carefully transferred into new pre-chilled tube. 600μl 
mixture of phenol acid and chloroform in the 2:1 ratio was then added into the transferred 
supernatant, vortexed briefly and subjected to centrifugation at 13,000rpm for 5min at 
4°C. The resulting uppermost layer was then transferred again to a new tube and 600μl of 
chloroform was added. Mixture was vortexed briefly twice and centrifuged at 13,000rpm 
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for 5min at 4°C. The uppermost supernatant was then transferred into a new tube, added 
with 3U/ μl of DNase I (Life Technologies, Carlsbad, CA, USA) and incubated at 37°C 
for 20min. Sample was then added with 500μl isopropanol, mixed thoroughly and 
incubated at -80°C overnight. The next day, mixture was then subjected to centrifugation 
at 13,000rpm for 10min at 4°C. The resulting white pellet should be visible after 
centrifugation and supernatant was carefully discarded. RNA pellet was then washed 
three times with 1ml 75% ethanol and subjected to centrifugation at 13,000rpm for 5min 
at 4°C. Supernatant was then discarded and pellet was air-dried for 5-10min and 
resuspended in 30-50μl of RNase free water gently. RNA suspension was then incubated 
in heatblock for 10min at 55°C. RNA concentration was determined with NanoDrop ND-
2000C (Thermo Scientific, Rockford, IL, USA) and the remaining of RNA was stored at 
-80°C. 
 
2.14.2 Quality control for total RNA 
The overall quality of the total RNA preparation was assessed by electrophoresis on 
denaturing agarose gel and polyacrylamide–urea (PAGE) gel. 
 
2.14.2.1  Agarose gel 
Denaturing agarose gel (1%) was prepared by dissolving 0.5g of agarose Life 
Technologies, Carslbad, CA, USA) in 43.5ml of H2O in microwave and cooled down to 
60°C in water bath. After the flask has cooled down to 60°C, 5ml of 10x MOPS running 
buffer, 1.5ml 12.3M (37%) formaldehyde and 1μl gel red (Biotium, Inc., CA, USA) were 
added to the agarose solution inside the fume hood. Mixture was then poured to the gel 
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cassette and was allowed to set. Sample was prepared by mixing 300ng of total RNA 
with 2μl of 10x MOPS running buffer, 3.5μl of 12.3M (37%) formaldehyde, 10μl of 
deionized formamide and 2μl of RNA loading buffer. Sample mixture was incubated at 
65°C for 10min and put on ice immediately. Sample was run with constant voltage of 
80V for 40min and gel was visualized using GelDoc (BioRad Laboratories, Herculer, 
CA, USA). 
 
2.14.2.2  PAGE gel 
Urea (3.6g) was dissolved with 2.8ml of 40% acrylamide/bis-acrylamide (29:1) solution 
and 0.75ml of 10x TBE buffer in 60°C water bath. Then 0.95ml H2O, 37μl of 10% 
ammonium persulfate (APS) and 7.5μl TEMED was added to the mixture. Solution 
mixture was poured to the gel cassette and allowed to set for 15min. Casted gel was pre-
run at 120V for 15min. Meanwhile, sample was prepared by combining 500ng of total 
RNA with 10μl deionized formamide, 3μl RNA loading buffer and 2μl 10x TBE buffer. 
Sample was incubated at 95°C for 5min and kept in ice immediately after heated. Sample 
was run at 120V for 2 hr. After running, gel was stained for 30min with staining buffer 
containing 1M NaCL and 15µl gel red for a total volume of 50ml. Gel was visualized 
using GelDoc (BioRad Laboratories, Hercules, CA, USA). 
 
2.15 mRNA quantitative real-time PCR 
A total of 500ng of RNA was used for first strand cDNA synthesis. cDNA was 
synthesized using the MultiScribe-based high-capacity cDNA archive kit (Applied 
Biosystems®, LifeTechnologies, Carlsbad, CA, USA). Quantitative real-time polymerase 
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chain reaction (QPCR) was performed to quantify genes encoding ANP, BNP, APLN, 
APJ, NPR1, NPR3, VEGF-A, BCL-2, B2M, and Actin according to manufacturer’s 
protocols using TaqMan gene specific primers and TaqMan universal master mix from 
Applied Biosystems® (LifeTechnologies, Carlsbad, CA, USA). Assay Id for all mRNAs 
validated were listed in Table 2.1. All QPCR reactions were conducted in triplicates on 
CFX96 Real Time System (BioRad Laboratories, Hercules, CA, USA). Beta-2 
microglobulin (B2M) was used as a normalizer to get the normalized expression for all 
genes and Actin was used as an inter-plate calibrator. 
Table 2.1 Assay Id of TaqMan gene specific primers used for quantitative real-time 
PCR 
Gene Assay Id 
ANP (NPPA) Rn00561661_m1 











2.16 Protein study 
2.16.1 Expression and purification of recombinant rat CSE 
The synthetic DNA sequence specifying rat CSE (Rattus norvegicus; GenBank Accession 
No. NP_058770) cloned into the vector, pJexpress404, were obtained from DNA2.0 
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(Menlo Park, CA, USA).  The coding sequence was designed with an N-terminal His6- 
tag to facilitate protein purification by immobilized metal affinity chromatography 
(IMAC) and custom optimized to E. coli preferred codons.  Authenticity of the synthetic 
coding fragment was verified by DNA sequencing.   
E. coli host strain BL21 (DE3) trxB (Novagen, Merck Millipore, Darmstadt, Germany) 
was used for the expression of recombinant rat CSE.  Mini-scale expression studies to 
determine the solubility of the rat protein were performed by growing the bacterial host 
containing the recombinant expression vector at 37ºC under ampicillin selection 
(100µg/ml) in 50ml of LB broth in a shaking flask. Isopropyl-β-D-thiogalactopyranoside 
(IPTG) was added when the culture reached an OD690 of 0.8 to a final concentration of 
0.5nM to induce the expression of the recombinant protein. 1ml culture samples were 
collected just prior to induction, at 2, and at 4hr post-induction for further analysis. The 
pattern of the recombinant protein accumulation was analyzed by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) analysis. Solubility of the fusion 
proteins was assessed by separating the total proteins into soluble and insoluble fractions 
as follows. 1ml of culture were pelleted by centrifugation, reconstituted in 300µl 
BugBuster protein extraction reagent (Novagen) and lysed at r.t by vortexing for 5min. 
Next, addition of 60µl of 6x SDS dissociation buffer (10.28% w/v SDS, 0.35 mM Tris–
HCl pH 6.8, 5% mercaptoethanol, 30% v/v glycerol, and 0.012% bromophenol blue) was 
carried out and then heated at 95ºC for 10min to solubilize the proteins. Centrifugation 
was performed to pellet the insoluble protein fraction at 12,000 g for 10min and the 
supernatant containing the soluble protein fraction was transferred to another tube. The 
insoluble fraction was washed with buffer (0.1% Na2HPO4, 0.8% NaCl, 0.02% KCl, and 
0.02% KH2PO4 adjusted to a final pH 7.3), collected with centrifugation and reconstituted 
in 300µl BugBuster (Novagen). Following that, 60µl of 6x SDS dissociation buffer was 
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added to both fractions, boiled for 10min, separated on a 12% SDS-PAGE gel and stained 
with coomassie blue. The expression profile was imaged by G:Box (Syngene, Synoptics 
Ltd, Cambridge, UK) and densitometry analysis of the relative band intensities was 
analyzed using the Quantity One quantitation software (Bio-Rad).  
For large scale purification, the bacterial host harboring the recombinant expression 
vector was grown at 37ºC under ampicillin selection (100µg/ml) in a shake flask 
containing 200ml of Terrific Broth (Conda Pronadisa,Spain). When the culture reached 
an OD690 of 0.8, IPTG was added to a final concentration of 0.5 mM to induce the 
expression of the recombinant protein. The culture was harvested at 4hr post-induction. 
Cells were pelleted at 5,000g for 10min at 4ºC and lysed in 40ml of BugBuster 
(Novagen) at room temperature by vortexing for 5min. The lysate was subjected to 
centrifugation at 8000g for 20min at 4ºC and supernatant was decanted off. The inclusion 
body pellet containing rat cystathionine-gamma lyase was washed with phosphate buffer 
and solubilized overnight at 4ºC in Wash buffer (5mM imidazole, 500mM NaCl, 100mM 
sodium phosphate, pH 8.0) containing 6M guanidium hydrochloride. Unsolubilized 
material was removed by centrifugation at 8500 rpm for 20min at 4ºC. The supernatant 
was clarified through a 0.45μm syringe filter and loaded onto the IMAC cartridge for 
purification under default program settings of the Denaturing IMAC method on the 
Profinia Purification System. The protein of interest was eluted with 4ml Elution buffer 
(250mM imidazole, 500mM NaCl, 100mM sodium phosphate, pH 8.0) containing 6M 
guanidium hydrochloride. The eluant was placed in a dialysis tubing (MWCO 10kDa) 
and dialysed overnight at 4ºC against 2L of 100mM sodium phosphate (pH 7.2) and a 
final dialysis against a further 2L of fresh phosphate buffer for 2hr.  The aggregated rat 
CSE was recovered from the dialysis tubing as a white precipitate and solubilized in 
1%SDS.  Protein quantitation was performed using the BCA assay as described below 
39 
 
(section 2.16.2) (Pierce, Rockford, IL, USA) and purity was analyzed by SDS-PAGE 
(16% gel) analysis followed by coomasie blue staining. 
 
2.16.2 Protein isolation and quantitation 
Heart tissue from the infarct and per-infarct area obtained from 4-5 rats per group and 
liver tissue obtained from 3 rats per group were ground into a fine powder using pestle 
and mortar under liquid nitrogen to prevent degradation. Total protein was extracted by 
adding 200-300μl lysis buffer (50mM Tris-HCL at pH 7.4, 150mM NaCl, 5mM EDTA, 
2% SDS, and 10% glycerol) containing a protease inhibitor and phosphatase inhibitor 
(Thermo Scientific, Waltham, MA, USA) for 1hr at 4ºC. Samples were then boiled at 
100ºC for 10min. The insoluble materials were pelletted at 14,000 rpm for 30 min at 4ºC. 
Total protein concentration was measured by the bicinchoninic acid (BCA) method 
(Thermo Scientific, Waltham, MA, USA) according to the manufacturer’s protocol. 
Sample was diluted 20x with the lysis buffer for concentration measurement. Standard 
curve was generated with BSA as standard. After adding samples and standards to the 
BCA reagents, reaction was incubated at 37ºC for 30min. Absorbance  reading at 562nm 
was obtained using Enspire 2300 multi-label reader (Perkin Elmer, MA, USA). 
Concentration of the total protein was measured from linear plots of the samples 
absorbance reading versus known concentration of BSA solution. 
 
2.16.3 Western blot analysis 
Bis-Tris SDS-PAGE was carried out according to the manufacturer’s instruction (Life 
Technologies, Carlsbad, CA, USA). NuPage 10% Bis-Tris pre-casted gels (Life 
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Technologies, Carlsbad, CA, USA) were used for the experiment. Protein samples (30μg) 
or 50ng of CSE recombinant protein (used as positive control for CSE analysis) were 
mixed with an equal volume of SDS-PAGE loading buffer (Life Technologies, Carlsbad, 
CA, USA) and heated at 70ºC for 10min. Electrophoresis was carried out at 150V for 
50min in 1X NuPage MES SDS running buffer (Life Technologies, Carlsbad, CA, USA). 
polyvinylidene difluoride (PVDF) membrane (BioRad Laboratories, Hercules, CA, USA) 
was activated in 100% methanol for 2-3min. The SDS-PAGE gel, PVDF membrane, 
scotchbrite and filter paper were soaked in pre-cooled (4°C) 1X NuPage Transfer buffer 
(Life Technologies, Carlsbad, CA, USA) for 10 min. They were assembled according to 
manufacturer’s instruction (BioRad Laboratories, Hercules, CA, USA) for electro-
transfer at 110V for 2hr in cold room (4°C). At the end of blotting, the PVDF membrane 
was stained with Ponceau S solution (Sigma Aldrich, St. Louis, MO, USA) to verify the 
efficiency of protein transfer. The membrane was then blocked with 5% non-fat milk in 
tris-buffered saline (1st Base) with 0.1% Tween 20 (TBS-T; Biorad) for 1hr at r.t. 
Subsequently, membrane was probed with the following primary antibodies: CSE, 
VEGF-A, BCL-2, cGKIα, α-tubulin and β-actin (SantaCruz, Biotechnology, Inc, Dallas, 
Tx USA) diluted in 5% skim milk in TBS-T and applied overnight at 4ºC. The membrane 
was subsequently washed 3 times in TBS-T, for 5min each time.  
For blot detection, goat anti-rabbit IgG HRP-conjugated or goat anti-mouse IgG HRP-
conjugated (Rockland Immunochemicals, PA, USA) at a dilution of 1:1000 in 5% skim 
milk in TBS-T, was added to the membrane. After 1 hr of incubation at r.t, the membrane 
was thoroughly washed as described above. Protein bands were visualized using 
chemiluminesence by adding ECL substrate solution containing luminol in peroxide 
buffer (Thermo Scientific, Waltham, MA, USA) to the membrane for 5min and then 
exposed using G:Box (Syngene, Synoptics Ltd, Cambridge, UK). Expression level of 
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protein of interest was measured by densitometry analysis using ImageJ software (1.42q, 
National Institutes of Health, Bethesda, MD, USA). Protein expression was quantified by 
normalizing it against β-actin or α-tubulin levels. 
 
2.17 miRNAs microarray 
miRNA profiling was performed on pooled samples of 3 animals per group per time point 
using LNATM-modified oligonucleotide (Exiqon, Vedbaek, Denmark) probes (Sanger 
miRBase release v11.0). Total RNA of the pooled samples (1μg) was first 3′-end-labeled 
with Hy3 dye using the miRCURY LNA™ Power Labeling Kit and hybridized on 
miRCURY LNA™ Arrays according to the manufacturer’s protocol (Exiqon, Vedbaek, 
Denmark) as follows. Samples were firstly incubated with calf intestinal alkaline 
phosphatase enzyme (CIP) for 30min at 37° C to remove the 5’ phosphates from the 
microRNA terminals. Reaction was stopped and RNA was denatured by incubation at 
95°C followed by snap cooling on ice. Next, a fluorescent label (Hy3™) was attached 
enzymatically to the 3’ end of the microRNAs in the total RNA samples by incubating 
samples with a fluorescent label for 2hr at 16°C protected from light. The labeling 
procedure was stopped by incubating reaction for 15min at 65°C and kept at 4°C until 
hybridization on the array. Hybridization of samples on the array chip was done using 
MAUI® hybridization system (BioMcro® Systems Inc, Salt Lake City, UT, USA). 
Labeled samples were denatured for 2min at 95°C after addition of hybridization buffer. 
The array chip was first pre-washed with wash buffer and primed with hybridization 
buffer. 50µl of labeled samples were injected to the chip and hybridized for 16hr at 56°C. 
At the end of the hybridization, chip was washed and scanned using InnoScan700, 
microarray scanner (Innopsys, Carbonne, France). Microarray data was analyzed using 
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GeneSpring GX v11 (Agilent Technologies Inc, Santa Clara, CA, USA). Background-
subtracted median signal intensity with conditions of at least four groups out of five 
groups expressing raw value of 300 was selected as a threshold value for inclusion of 
significantly detected miRNAs followed by normalization using global quantile 
normalization. Differentially regulated miRNAs (all infarcted groups versus healthy 
control) with fold change (FC) ≥1.1 and ≤−1.1, at least in one group or more, were 
considered and subjected to unsupervised hierarchical clustering analysis. Hierarchical 
clustering plot (heatmap) of miRNAs was generated using Multiple Experiment Viewer 
v4.9 software with average linkage and Euclidean distance metric as clustering criteria 
(Dana-Farber Cancer Institute, Boston, MA, USA). Top 13 miRNAs from this list were 
selected for further validation with miRNAs QPCR.  
 
2.18 miRNAs QPCR 
Stem-loop real-time RT-PCR quantification of miRNA expression was performed using 
TaqMan microRNA assays (Applied Biosystems®, LifeTechnologies, Carlsbad, CA, 
USA) with specific miRNA primers according to the manufacturer's protocol. A total of 
10ng of total RNA was used for reverse transcription reaction and followed by QPCR 
using TaqMan universal master mix from Applied Biosystems® (LifeTechnologies, 
Carlsbad, CA, USA). Assay Id for all miRNAs validated were listed in Table 2.2. All 
QPCR reactions were conducted in triplicates on CFX96 Real Time System (BioRad 
Laboratories, Hercules, CA, USA). 4.5sRNA was used as a normalizer to get the 




Table 2.2 Assay Id of TaqMan miRNAs specific primers used for quantitative real-
time PCR 


















2.19 Statistical analysis 
Data are presented as mean ± standard error of mean (SEM). To test for statistical 
significance between-group comparisons of echocardiographic indexes, hemodynamic 
parameters and miRNAs expression were performed using a 2-way ANOVA with 
repeated measures followed by pair-wise comparisons using Bonferroni’s post-test. The 
ANOVA model for echocardiographic indexes included healthy control versus treatment 
and baseline versus 2 or 7 days after MI as factors, as well as the interaction between the 
two factors. The ANOVA model for hemodynamic parameters and miRNAs expression 
included healthy control versus treatment and day 2 versus day 7 as factors, as well as the 
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interaction between the two factors. For other comparisons, one-way ANOVA followed 
by the Bonferroni’s post hoc test and the unpaired Student’s t-test were used when 
appropriate. Differences were considered significant when P<0.05. All statistical analyses 
were performed using GraphPad Prism® software version 5.04 for Windows (GraphPad 
















3.1 Animal survival 
To evaluate the effect of GYY on the response to cardiac injury, all rats except the sham 
group underwent LAD ligation. All the rats from the sham-operated group survived the 
surgical procedure (n=6/time-point). In total, 12 out of 84 rats that underwent LAD 
ligation died within 24hr after surgery (treatment group as indicated in Figure 2.1): 3 out 
of 21 MI (14.3%), 3 out of 21 placebo (14.3%), 2 out of 20 GYY (10%) and  4 out of 22 
PAG (18.2%). Thus, 9 infarcted rats /group/time-point were subsequently included in this 
study. 
 
3.2 Effect of GYY on the H2S system during ischemic injury 
To assess the effect of GYY on plasma H2S level, plasma were collected from rats from 
each group and assessed through HPLC. Evaluation on plasma H2S level showed that 
exogenous application of GYY induced a 2.8 fold increase in plasma H2S relative to 
sham rats (P<0.0001) at both time points (Figure 3.1). Similarly, plasma H2S level in 
GYY-treated animals (2265.4 ± 231.5 and 3078.5 ± 417.1nmol/L) were significantly 
enhanced at both time-points of evaluation compared to untreated MI animals (1234.7 
±86.8 and 1452.0 ± 134.7nmol/L; P<0.01 and P<0.001), placebo- (1055.9 ± 80.5 and 
1704.7 ± 244.8nmol/L; P<0.001 and P<0.01) and PAG-treated rats (1352.7 ± 144.0 and 




Figure 3.1 Plasma H2S levels at day 2 and day 7 post-MI. Assessment of plasma H2S 
levels by HPLC of healthy sham-operated rats, infarcted untreated rats (MI), placebo-, 
GYY-, and PAG-treated rats (n=5-6/group; P<0.0001 vs. Sham). Data were presented as 
mean ± SEM.   
 
 
We then examined if GYY treatment increased the expression of CSE. Authenticity of 
the synthetic coding fragment of rat CSE was firstly verified by DNA sequencing 
(Figure 3.2A). A polyhistidine tag to facilitate protein purification by IMAC was 
incorporated at the N-terminus. Gene expression under the T5 promoter resulted in the 
production of an expected 44.5 kDa protein of amino acid sequence as shown in Figure 
3.2B. Rat CSE was highly expressed in bacteria and accumulated rapidly to 34.6% of 
total bacterial proteins at 2hr post induction as determined by densitometric band 
quantitation with rolling disk baseline correction set at a rolling disk radius of 50 pixels.  
No further increase in band intensity was observed at 4hr post-induction (Figure 3.2B). 
Partitioning of total proteins into soluble and insoluble protein fractions showed that rat 
CSE was produced primarily in the aggregate form. As CSE is abundantly expressed in 
liver78, 132, we evaluated CSE protein expression level in liver tissue. We found that CSE 
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protein expression level was not significantly altered in all groups at both time-points as 
shown by densitometry analysis and quantification (Figure 3.2C and D). While the 
effect of daily treatment with PAG did not alter plasma H2S level and CSE protein 
expression level, its enzyme activity in liver tissue of PAG-treated rats was significantly 
reduced (Figure 3.2E). Homogenates of livers from PAG-treated animals produced 31-
fold less H2S (nmol/mg of soluble protein) at day 2 (0.20 ±0.01) and day 7 post-MI (0.14 
±0.01) compared to placebo-treated animals (5.97±0.37, and 4.38 ±0.31; P<0.0001 for 
both) suggesting that dose of PAG used was efficient to inhibit CSE activity (Figure 
3.2E). These results demonstrated that GYY treatment increased plasma H2S level but 




Figure 3.2 Evaluation of GYY treatment on CSE during ischemic injury. (A) Amino 
acid sequence of expressed recombinant rat CSE. Underlined sequence represents 
position of the polyhistidine tag. (B) Expression pattern of rat CSE in E. coli strain BL21 
(DE3) trxB. Red arrow indicates the expressed CSE at the expected 44.5 kDa position. 
(M = Precision Plus Protein™ All Blue Standards) (C) Representative blot showing the 
expression of CSE protein in liver tissue (D) Densitometry analysis of CSE expression 
level in liver tissue normalized to α-tubulin (n=2-3) (E) Measurement of tissue H2S-
synthesizing enzyme activity in liver tissue at 2 days and 7 days post-MI in placebo- and 
PAG-treated rats. (n=6/group/time-point; **P<0.01 vs. day 2). Data were presented as 
mean ± SEM. 
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3.3 Therapeutic effects of post-ischemic treatment with GYY in the acute and late 
phases following MI 
3.3.1 Post-ischemic treatment of GYY preserved LV function and structure 
We evaluated the effect of post-ischemic treatment of GYY with transthoracic 
echocardiography. We found that, at both time points, GYY treatment led to attenuation 
of LV remodeling and preservation of cardiac function. At 2 days post-MI, treatment 
with GYY preserved the cardiac structure as seen from the wall thickness measurement 
during diastole (Figure 3.3A) and systole (Figure 3.3B). LV wall thickness in diastole 
and systole were comparable to baseline and healthy control (sham) whereas during 
systole, MI-, placebo- and PAG-treated rats displayed significant thinner wall compared 
to GYY-treated rats (P<0.0001, P<0.001 and P<0.01). Treatment with GYY also 
prevented early adverse cardiac remodeling as LV internal dimension in diastole 
(LVIDd) and systole (LVIDs) was comparable to baseline and sham animals, and LVIDs 
was significantly preserved compared to MI (P<0.001), placebo (P<0.01) and PAG 
(P<0.0001) group (Figure 3.3C and D).  
Similar results were observed at 7 days post-MI. LV wall thickness during diastole in 
GYY-treated rats was still comparable to baseline and sham group (Figure 3.3E). 
Although LV wall thickness in systole (Figure 3.3F), LVIDd (Figure 3.3G) and LVIDs 
(Figure 3.3H) of GYY-treated rats were statistically significantly different compared to 
baseline (P<0.05, P<0.01 and P<0.001 respectively), these values were close to those of 
the sham animals. Moreover, LV wall thickness during systole in GYY-treated rats was 
still significantly thicker compared to MI (P<0.01) and PAG (P<0.05) group (Figure 
3.3F). Similarly, LVIDs was significantly smaller compared to MI- (P<0.0001), placebo- 
(P<0.0001) and PAG- (P<0.0001) treated rats (Figure3.3H). In contrast, the other 
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infarcted groups exhibited a marked decrease in wall thickness during systole (Figure 
3.3B) and marked increase in LVIDs (Figure 3.3D) when compared to sham group and 
baseline.  
 
Figure 3.3 Echocardiographic evaluation of LV remodeling. LV wall thickness of 
healthy sham-operated rats, infarcted untreated rats (MI), placebo-, GYY-, and PAG-
treated rats were measured in (A) diastole and (B) systole 2 days post-MI and (E-F) 7 
days post-MI. LV internal dimension of the animals were also measured in (C) diastole 
and (D) systole 2 days post-MI and (G-H) 7 days post-MI. Group-time interaction: n.s, 
not significant; *a P<0.05 vs. Sham; **a P<0.01 vs. Sham; #a P<0.001 vs. Sham; ##a 
P<0.0001 vs. Sham; *b P<0.05 vs. GYY; **b P<0.01 vs. GYY; #b P<0.001 vs. GYY; 
##b P<0.0001 vs. GYY (n=6 for sham/time point, n=9 for other groups/time point). Data 
were presented as mean ± SEM. 
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Cardiac dysfunction was also evaluated based on 4 parameters: (1) left ventricular end-
diastolic volume (LVEDV), (2) left ventricular end-systolic volume (LVESV), (3) left 
ventricular fractional shortening (FS), and (4) left ventricular ejection fraction (EF). 
Attenuation of cardiac dysfunction in GYY-treated group can be observed at both time-
point post-MI. At day 2 post-MI, measurement readouts for LVEDV (Figure 3.4A), 
LVESV (Figure 3.4B), FS (Figure 3.4C) and EF (Figure 3.4D) in GYY-treated rats 
were comparable to sham group and to the baseline reading. In addition, LVESV, a 
cardinal post-MI predictor of adverse remodeling and increased risk of adverse clinical 
outcomes133, was significantly preserved in GYY-treated group (0.079±0.016ml) when 
compared to MI (P<0.01), placebo (P<0.001) and PAG (P<0.0001) group (Figure 3.4B). 
Moreover, FS (48.82±4.19%; Figure 3.4C) and EF (83.54±2.40%; Figure 3.4D) at day 2 
post-MI were significantly preserved compared to MI (P<0.001 and P<0.0001 
respectively), placebo (P<0.01 and P<0.001) and PAG (P<0.001 and P<0.0001) group. 
At day 7 post-MI, measurement of LVEDV in GYY-treated rats was not statistically 
significant compared to baseline and sham rats while other infarcted groups had 
significantly elevated LVEDV relative to baseline (Figure 3.4E). Importantly, LVESV 
was significantly preserved in GYY-treated group (0.136±0.022ml) when compared to 
MI (P<0.001), placebo (P<0.0001) and PAG (P<0.0001) group (Figure 3.F). 
Furthermore, the decrease in FS (41.13±3.08%; Figure 3.4G) and EF (75.70±2.22%; 
Figure 3.4H) in GYY-treated rats, when compared to its baseline readings 
(54.94±2.97%; P<0.001 and 88.50±1.11%; P<0.05), were markedly ameliorated, 
contrasting the severe decrease observed in FS and EF (P<0.0001, respectively) in the 





Figure 3.4 Echocardiographic evaluation of LV function. (A) LV end-diastolic 
volume and (B) LV end-systolic volume of healthy sham-operated rats, infarcted 
untreated rats (MI), placebo-treated, GYY-treated and PAG-treated rats were evaluated 2 
days post-MI and (E-F) 7 days post-MI. (C) LV fractional shortening and (D) ejection 
fraction were also evaluated 2 days post-MI  and (G-H) 7 days post-MI. Group-time 
interaction: n.s, not significant; *a P<0.05 vs. Sham; **a P<0.01 vs. Sham; #a P<0.001 
vs. Sham; ##a P<0.0001 vs. Sham; *b P<0.05 vs. GYY; **b P<0.01 vs. GYY; #b 
P<0.001 vs. GYY; ##b P<0.0001 vs. GYY (n=6 for sham/time point, n=9 for other 
groups/time point). Data were presented as mean ± SEM. 
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Additionally, we also performed hemodynamic analyses to further confirm the effect of 
GYY treatment. As seen in Table 3.1, hemodynamic analyses revealed that preservation 
of cardiac function in GYY-treated rats was paralleled by conservation of LV end-
diastolic pressure (LVEDP) at both-time points (3.38 ± 0.37 mmHg and 3.58 ± 
0.39mmHg) and that these values were comparable to that of sham group (2.06 ±0.34 
mmHg and 2.82 ± 0.15 mmHg). In contrast, all other infarcted groups had significantly 
higher LVEDP than sham group (in mmHg): MI rats (4.62 ± 0.65 and 4.86 ± 0.27, 
P<0.05, for days 2 and 7 respectively), placebo- (4.46 ± 0.32; P<0.05, and 5.26 ± 0.61; 
P<0.01), and PAG-treated (4.94 ± 0.63; P<0.001, and 4.92 ± 0.37; P<0.05) (Table 3.1). 
GYY also preserved cardiac output as demonstrated with readout values that were 
comparable to sham animals at both time-points. Notably, cardiac output in GYY group 
at 2 days post-MI were also significantly higher compared to all infarcted groups (P<0.05 
respectively) (Table 3.1). There was no significant difference in the stroke volume of 
GYY-treated rats compared to that of sham animals at both time-points, but the stroke 
volume of other infarcted groups was significantly lower when compared to sham 
animals (P<0.05) at day 7 post-MI. There was no significant change in other 
hemodynamic parameters across all groups at both time-points (Table 3.1). Collectively, 
these results demonstrated that GYY attenuated LV remodeling and preserved cardiac 










Table 3.1 Hemodynamic parameters in healthy sham-operated rats, infarcted 
untreated rats (MI), infarcted placebo-, GYY-, and PAG- treated rats, 2 and 7 days 
after myocardial injury.*  
 
*LVEDP, left ventricular end-diastolic pressure; BPM, beats per minute; s, seconds; ms, 
milliseconds. Data were presented as mean ± SEM. Group-time interaction statistical significance 












LVEDP (mmHg)     
2 days post-MI 2.06±0.34 4.62±0.65 *a 4.46±0.32 *a 3.38±0.37 4.94±0.63 **a 
7 days post-MI 2.82±0.15 4.86±0.27 *a 5.26±0.61 **a 3.58±0.39 4.92±0.37 *a 
      
Mean Pressure 
(mmHg)      
2 days post-MI 27.10±2.19 23.76±0.96 26.16±1.27 25.32±1.67 29.18±1.65 
7 days post-MI 26.27±3.40 29.21±1.43 29.42±1.33 25.29±1.35 29.52±1.66 
      
Systolic Duration (s)      
2 days post-MI 0.10±0.003 0.10±0.003 0.10±0.003 0.10±0.004 0.09±0.002 
7 days post-MI 0.09±0.004 0.10±0.003 0.10±0.003 0.09±0.002 0.10±0.003 
      
Diastolic Duration (s)      
2 days post-MI 0.09±0.01 0.11±0.005 0.10±0.01 0.10±0.004 0.10±0.004 
7 days post-MI 0.11±0.005 0.11±0.01 0.11±0.005 0.10±0.005 0.10±0.01 
      
Cycle Duration (s)      
2 days post-MI 0.19±0.01 0.21±0.01 0.20±0.01 0.20±0.01 0.20±0.01 
7 days post-MI 0.20±0.01 0.21±0.01 0.20±0.01 0.19±0.01 0.20±0.01 
      
Heart Rate (BPM)      
2 days post-MI 323.52±19.57 292.04±9.03 303.80±10.56 305.37±9.86 308.18±8.23 
7 days post-MI 303.93±8.30 300.23±12.21 296.49±10.21 319.44±9.00 303.84±12.66 
      
Max dP/dt (mmHg/s)      
2 days post-MI 3025.69±426.61 2669.92±246.37 2937.20±226.25 2789.54±220.28 3642.22±260.62 
7 days post-MI 3777.48±539.87 3434.60±348.65 3590.00±264.07 3077.21±215.94 3535.51±284.44 
      
Contractility Index 
(1/s)      
2 days post-MI 100.68±4.31 93.28±3.80 98.75±2.15 95.10±2.34 102.59±2.50 
7 days post-MI 108.25±3.97 97.96±3.33 99.92±3.36 101.33±3.01 103.81±2.97 
      
Min dP/dt (mmHg/s)      
2 days post-MI -2226.92±347.74 -1854.88±171.62 -2159.77±175.48 -1999.00±208.22 -2437.31±204.06 
7 days post-MI -2818.28±474.04 -2489.29±296.19 -2549.04±229.01 -2174.41±138.82 -2539.06±244.10 
      
Tau (ms)      
2 days post-MI 15.43±1.31 20.46±1.19 18.14±1.07 19.44±1.35 17.73±1.00 
7 days post-MI 15.66±1.93 18.04±1.59 19.01±2.76 17.03±1.05 14.36±2.19 
      
Cardiac Output 
(mL/min)      
2 days post-MI 51.38±2.20 44.37±3.18 *b 44.37±2.67 *b 57.19±3.35 44.38±4.70 *b 
7 days post-MI 66.08±4.73 48.43±3.14 *a 48.25±4.03 *a 60.29±3.27 46.75±4.21 **a 
      
Stroke volume 
(mL/beat)      
2 days post-MI 0.16±0.01 0.15±0.01 0.15±0.01 0.19±0.01 0.15±0.02 




3.3.2 Post-ischemic treatment of GYY reduced LV fibrosis 
Fibrosis has been shown to play a critical role in LV remodeling and LV dysfunction 
post-MI134. In order to investigate the effect of post-ischemic treatment of GYY on LV 
fibrosis, morphometric studies on heart tissue were performed. As seen in Figure 3.5A 
and B, GYY treatment preserved LV dimensions comparable to sham at day 2 and day 7 
post-MI. In addition, GYY-treated rats displayed significantly smaller LV cross-sectional 
area containing fibrosis (as indicated by area stained green) at day 2 (Figure 3.5A) and 
day 7 (Figure 3.5B) post-MI. Quantification of the fibrotic area confirmed that GYY 
treatment resulted in significantly lower percentage of fibrosis (8.0 ±1.4% and 15.3 ± 
3.4%) compared to MI (38.1 ±5.4%; P<0.01 and 36.9 ±4.6%; P<0.05), placebo (39.4 ± 
6.5%; P<0.01 and 36.7 ± 8.0%; P<0.05) and PAG (39.6 ±5.4%; P<0.01 and 39.3 ±2.4%; 
P<0.01) group (Figure 3.5C). Therefore, in agreement with the results of the 
echocardiographic data, treatment with GYY attenuated adverse LV remodeling and 





Figure 3.5 Morphometric evaluations of explanted hearts after treatment. 
Representative mid-ventricular cross-section of Masson’s trichrome-stained sections 
(40x) of infarcted untreated rats (MI), infarcted placebo-, GYY-, and PAG- treated rats, 
(A) 2 days and (B) 7 days after MI showing more conserved LV dimensions and less 
collagen deposition in GYY-treated rats. Scale bars, 1,000µm. (C) Measurement of the 
percentage of LV area containing fibrosis at both time-points (n=7-8/group). Data were 










3.3.3 Post-ischemic treatment of GYY enhanced vascularization in the infarct 
area 
Angiogenesis is necessary for cardiac repair following cardiac injury27. Thus, the effect 
of GYY on vascular density was assessed by performing immunofluorescence staining 
against rat endothelial cell antigen-1 (RECA-1) and α-smooth muscle actin (SMA) on LV 
scar region of infarcted hearts in all treatment groups (Figure 3.6). RECA-1-positive 
(RECA-1+) vessels were stained in red and SMA-positive (SMA+) vessels were stained in 
green, whereas nuclei were stained in blue. Disruption of blood vessels or reduction in 
RECA-1+ and SMA+ vessels, at both evaluation time-point, could be observed in 
infarcted MI group (Figure 3.6A and B), placebo-treated group (Figure 3.6C and D) and 
PAG-treated group (Figure 3.6G and H). In contrast, GYY treatment seemed to promote 
angiogenesis as indicated by a marked increase in the number of RECA-1+ vessels at day 
2 (Figure 3.6E) and day 7 (Figure 3.6F) post-MI. The number of blood vessels was then 
quantified by counting RECA-1+ and SMA+ vessels in the LV scar area per 200x field. 
Based on the quantification presented in Figure 3.6I, more of RECA-1+ blood vessels 
were seen in GYY-treated hearts at day 2 (118.06 ±11.98) and 7 post-MI (110.42 ±14.81) 
compared to MI-treated (45.72 ±3.21 and 37.51 ±11.58; P<0.01 respectively), placebo-
treated (41.08 ± 11.69; P<0.001 and 36.74 ± 6.73; P<0.01) and PAG-treated groups 
(42.07 ±10.03 P<0.001 and 37.77 ±6.57; P<0.01). Likewise, SMA+ blood vessels were 
more abundantly observed within the scar area of rats treated with GYY compared to 
PAG-treated rats, 2 days after infarct (P<0.05) and when compared to all the other 
infarcted groups at day 7 post-MI (P<0.001 for all comparisons) (Figure 3.6J). These 




Figure 3.6 Evaluation of vascularization in the infarct area post-MI. Figure to 




Figure 3.6 Evaluation on vascularization in the infarct area post-MI. Representative 
micrographs of the LV scar area stained with rat endothelial cell antigen-1 (RECA-1+; 
red)  and α-smooth muscle actin (SMA+; green) and DAPI (nucleus; blue)  to visualize 
blood vessels in (A, B) infarcted untreated rat hearts (MI), and in treated rats with (C, D) 
placebo, (E, F) GYY, and (G, H) PAG, at days 2 and 7 after MI as indicated; (200x; n=3-
4/group/time-point). Individual immunofluorescence staining can be observed underneath 
the merged image. Scale bar indicates 100µm.  (I) Quantification of RECA-1+ blood 
vessels density among groups at day 2 and 7 post-infarct (**P<0.01 vs. GYY and 
***P<0.001 vs. GYY to each respective time-point). (J) Quantification of SMA+ blood 
vessels density among groups at day 2 and 7 post-infarct (*P<0.05 vs. GYY and 
**P<0.01 vs. GYY to each respective time-point; n.s, not significant). Data were 
presented as mean ± SEM. 
 
3.5 Effect of GYY treatment on neurohormonal activation in the acute and late 
phases following MI 
3.4.1 Post-ischemic treatment of GYY increased plasma ANP and BNP levels 
In order to investigate whether GYY treatment has effect on neurohormonal activation, 
plasma samples from each group were evaluated for their ANP and BNP levels. A trend 
towards increased plasma ANP level in GYY-treated animals could be observed at day 2 
post-MI (Figure 3.7A). The elevated level of ANP in GYY-treated groups was 
significantly maintained at day 7 (271.4 ± 66pmol/L) compared to reduced level observed 
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in sham (81.1 ± 12.4pmol/L), MI (97.2 ± 27.2pmol/L), placebo (88.1 ± 32.9pmol/L) and 
PAG group (75.33 ± 9.7pmol/L) (P<0.05, respectively) (Figure 3.7A). Plasma BNP level 
was initially comparable among groups at day 2 post-injury but at day 7, BNP level was 
significantly higher in GYY-treated rats when compared to sham (105.3 ± 9.3pg/mL vs. 
59.3 ±3.0pg/mL, P<0.01), as well as to MI (67.7 ± 5.4pg/mL, P<0.01) and PAG-treated 
animals (64.7 ± 6.7 P<0.01) (Figure 3.7B). These results demonstrated that GYY 
enhanced ANP and BNP levels at the late phase following MI. 
 
Figure 3.7 Assessment on plasma cardiac NPs levels. Plasma (A) ANP and (B) BNP 
levels were evaluated in healthy sham-operated rats, infarcted untreated rats (MI), 
infarcted placebo-, GYY-, and PAG- treated rats, 2 and 7 days after MI (*P<0.05 vs. 




3.4.2 Post-ischemic treatment of GYY affected cardiac NPs and their receptors at 
mRNA level 
To evaluate whether treatment of GYY has any effect on NPs and NPs receptors at 
mRNA level, we performed QPCR on heart tissue collected from infarct and peri-infarct 
area. At day 2 post-MI, mRNA expression of cardiac ANP (NPPA mRNA) was 
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significantly elevated in GYY-treated rats compared to all other animal groups (Figure 
3.8A). Expression of NPPA was increased by 10 fold in GYY-treated rats (10.4 ± 1.9) 
relative to sham animals (P<0.001), and 2-fold relative to the other infarcted groups (i.e. 
MI, placebo- and PAG-treated, P<0.05 respectively; Figure 3.8A). At day 7, NPPA 
expression level of GYY-treated animals was not statistically significant when compared 
to sham group; while in the other infarcted groups, NPPA level remained significantly 
elevated relative to sham group (Figure 3.8B).  In contrast, there were no significant 
differences in BNP mRNA levels (NPPB) in heart tissue between sham and all the 
infarcted groups at both time-points (Figure 3.8C and D). mRNA expression level of 
NPR1, the guanylyl-cyclase receptor for ANP and BNP, was initially similar among all 
groups at day 2 post-MI (Figure 3.8E), but was found to be down-regulated in MI rats 
compared to sham (P<0.01), GYY- (P<0.05) and PAG- treated animals (P<0.05) at day 7 
post-MI (Figure 3.8F).  NPR3 (clearance receptor for NPs) mRNA expression level was 
overall down-regulated in all infarcted groups relative to sham group at both time-points 
(Figure 3.8G and H). However, it was noted that cardiac NPR3 expression in GYY-
treated animals was less repressed than in the other infarcted groups, and was 
significantly higher than in PAG-treated rats at day 2 after injury (P<0.05; Figure 3.8G). 
These results demonstrated that treatment of GYY influenced mRNA expression level of 




Figure 3.8 Evaluation of mRNA level of NPs and their receptors. Expression of 
NPPA, NPPB, NPR1, NPR3 mRNA level at (A, C, E, G) day 2 post-MI and (B, D, F, H) 
day 7 post-MI in healthy sham-operated rats, infarcted untreated rats (MI), infarcted 
placebo-, GYY-, and PAG- treated rats (n=6/group/time point). n.s, not significant; 
*P<0.05; **P<0.01; ***P<0.001; ****P<0.0001 vs. sham. Data were presented as mean 
± SEM.     
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3.4.3 Effect of GYY treatment on other neurohormones	
To evaluate whether GYY treatment influences other neurohormones, their levels in the 
plasma were measured. There was no difference in plasma aldosterone level in GYY-
treated rats compared to sham, MI and placebo group at both time-points (Figure 3.9A), 
although it was noted that plasma aldosterone level in PAG-treated rats was significantly 
lower compared to sham and GYY-treated rats (P<0.01 respectively), as well as to MI 
and placebo rats (P<0.05 respectively) at day 2 post-MI (Figure 3.9A). Plasma 
endothelin level (Figure 3.9B) and plasma renin activity (PRA; Figure 3.9C) remained 
unaltered among the groups at both time-points. These results showed that GYY 
treatment had no effect on plasma aldosterone, endothelin and PRA. 
Apelin, an endogenous ligand for the Ang 2 receptor-like 1 (APJ), has been reported to 
exert cardioprotective effect in acute MI135. As such, we evaluated the effect of GYY 
treatment on apelin expression. Cardiac apelin mRNA level was found to be up-regulated 
in GYY-treated rats compared to PAG at day 2 post-injury (P<0.05) (Figure 3.9D).  At 
day 7 post-MI, GYY-treated rats displayed apelin mRNA level that was significantly 
elevated compared to untreated infarcted (MI) animals (P<0.001), as well as in placebo- 
(P<0.05) and PAG-treated animals (P<0.0001), although not statistically significant when 
compared to sham animals. Whereas, PAG-treated animals demonstrated down-
regulation of apelin mRNA relative to sham (p<0.05) at day 7 post-MI (Figure 3.9D). 
Likewise, as seen in Figure 3.9E, there was an overall down-regulation of APJ mRNA, 
as an effect of infarction, at day 2 in MI-, placebo-, and PAG-treated group. However, 
importantly, GYY treatment prevented this down-regulation as observed from a similar 
APJ mRNA level to the sham group. This resulted in a significant difference when 
compared to that of PAG treatment (P<0.05). At day 7, APJ mRNA level was maintained 
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in GYY group while it remained down-regulated in PAG-treated animals relative to both 
sham and GYY-treated rats (P<0.05 and P<0.01; Figure 3.9E). 
Collectively, these results demonstrated that GYY increased apelin expression while 
preventing down-regulation of its receptor, APJ. This is important as apelin is involved in 
cardioprotection. 
 
Figure 3.9 Effect of GYY treatment on other neurohormones. Plasma (A) 
aldosterone, (B) endothelin and (C) plasma renin activity (PRA) levels in sham, infarcted 
untreated (MI) rats, placebo-, GYY-, and PAG-treated rats were analyzed at day 2 and 7 
following myocardial infarction (n=3/group). Cardiac mRNA levels for (D) apelin and 
(E) APJ for the above-mentioned groups were also evaluated 2 and 7 days post-injury 
(n=6/group). *P<0.05 vs. sham; **P<0.01 vs. sham; n.s, not significant. Data were 
presented as mean ± SEM. 
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3.5 Post-ischemic treatment of GYY increased plasma cGMP and NO levels in the 
late post-MI period 
cGMP is the intracellular second messenger of ANP and BNP upon binding to NPR194. 
As such, we examined the downstream effect from the increased ANP and BNP. In 
agreement to the previously observed elevation of plasma ANP and BNP level in GYY-
treated animals at day 7 post-MI, plasma cGMP was also found to be significantly 
elevated at this time-point in animals treated with GYY (6.15 ± 1.84 pmol/mL) when 
compared to sham rats (1.33 ± 0.30 pmol/mL), MI- (1.37 ± 0.25 pmol/mL), placebo-  
(1.76 ± 0.41 pmol/mL) and PAG-treated rats (1.86 ±  0.27 pmol/mL;  P<0.05, 
respectively) (Figure 3.10A). It has been known that cGMP is also generated by the 
activation of soluble guanylate cyclase by nitric oxide (NO)95. Thus, NO metabolites (i.e. 
nitrite (NO2¯) and nitrate (NO3¯)) levels in plasma were investigated. Plasma NO level in 
GYY-treated rats was notably increased compared to sham animals at day 7 post-injury 
(P<0.05) (Figure 3.10B). In addition, protein expression level of cGKIα, one of the 
downstream effectors of cGMP95, in the heart tissue was determined through 
immunoblotting. Interestingly, it was observed that in GYY-treated animals, cGKIα 
protein was significantly increased compared to sham animals (P<0.01), at day 2 post-MI 
as seen in Figure 3.10C and its quantification in Figure 3.10D, while protein expression 
of cGKIα remained unchanged among all groups at day 7 post-MI. These results 
demonstrated that GYY treatment induced increases in plasma NO together with the 




Figure 3.10 Effect of GYY treatment on plasma cGMP and NO levels post-MI. 
Evaluation of plasma (A) cGMP, (B) NO (nitrite/nitrate) level at both time-points in 
sham-operated, infarcted untreated (MI), placebo-, GYY-, and PAG- treated rats 
(*P<0.05 vs. sham; n=3-4/group/time-point) (C) Representative blots showing the 
expression of cGK1α protein level in heart tissue from the infarct and peri-infarct area at 
both time-points. Gray line indicating separation of images from 2 different blots (D) 
Densitometry analysis on expression of cGKα protein levels normalized to β-actin 





3.6 Effect of GYY on cardiac VEGF-A and BCL-2 expression in the acute and late 
phases following MI 
In order to investigate whether the cardioprotective effect exerted by GYY following 
acute MI was associated with modulation of the expression of VEGF-A and BCL-2, both 
of their mRNA and protein level were assessed. Evaluation on VEGF-A mRNA 
expression level in tissue from the infarct and peri-infarct zones demonstrated significant 
down-regulation in the infarcted groups at both time-points of evaluation (Figure 3.11A). 
At day 2 post-infarction, VEGF-A levels in GYY-treated animals were less repressed 
(P<0.05 relative to sham group), while animals from MI (P<0.001), placebo (P<0.0001) 
and PAG (P<0.0001) groups displayed significant suppression of VEGF-A mRNA 
expression relative to sham groups (Figure 3.11A). There were no differences in mRNA 
expression of the anti-apoptotic gene BCL-2 among the groups at day 2 post-ischemic 
injury (Figure 3.11B). However, it was noted that BCL-2 expression was increased in 
GYY- compared to PAG-treated hearts (P<0.05) at day 7 (Figure 3.11B).  At protein 
level, high inter-individual variation was observed among all groups at both time-points 
(Figure 3.11C and D). Only a trend towards increased BCL-2 (Figure 3.11E) and 
VEGF-A (Figure 3.11G) protein could be seen at day 2, whereas both BCL-2 (Figure 
3.11F) and VEGF-A (Figure 3.11H) protein at day 7 were comparable among all groups. 
These results suggested that GYY might modulate VEGF-A and BCL-2 at different 




Figure 3.11 Effect of GYY on cardiac VEGF-A and BCL-2 expression at both time-
points. mRNA expression level of (A) VEGF-A and (B) BCL-2 in heart tissue from the 
infarct and peri-infarct area of sham-operated, infarcted untreated (MI), placebo-, GYY 
and PAG- treated rats, at days 2 and 7 after MI (*P<0.05; **P<0.01; ***P<0.001 and 
****P<0.0001; n=3-6/group/time-point). (C-D) Representative blots for VEGF-A and 
BCL-2 protein expression in rat hearts, as described above (n=4-5/group). Gray line 
indicating separation of images from 2 different blots. Densitometry analysis was 
performed for BCL-2 protein levels at (E) day 2 and (F) day 7 post-MI and VEGF-A 
protein levels at (G) day 2 and (H) day 7 post-MI. Protein expressions were normalized 
to β-actin. Data were presented as mean ± SEM. 
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3.7 Effect of post-ischemic treatment of GYY on miRNA profiles in the acute and 
late phases following MI  
3.7.1 miRNA profiles in the acute and late phases following MI	
To investigate effect of GYY treatment on miRNAs response to cardiac injury, we 
carried out miRNAs profiling of total RNA isolated from heart tissue from the LV infarct 
and peri-infarct areas from pooled samples (i.e. three samples/group/time-point were 
pooled together). miRNAs profiling detected 140 dysregulated miRNAs at 2 days post-
MI (Appendix 1) and 142 dysregulated miRNAs at day 7 post-MI (all infarcted groups 
vs. healthy sham) (Appendix 2). Analysis was done in comparison to sham group in 
order to eliminate those miRNAs that are related to muscle injury upon lateral 
thoracotomy. Box whisker plot for both time-points after quantile normalization 
demonstrated that the normalized intensity values were of similar distribution among all 
groups suggesting that all technical and sample variations have been normalized (Figure 
3.12). Few outliers were observed at day 2 of PAG-treated group as seen from box 
whisker plot (Figure 3.12A) namely miR-30c, miR-30e, miR-342-3p, miR-370, miR-378 





Figure 3.12 Box whisker plots of quantile normalized intensity values for both time-
points. Box whisker plot for (A) day 2 and (B) day 7 post-MI. Red line indicates outliers. 
 
Hierarchical clustering plot with average linkage and Euclidean distance metric was 
plotted from the fold change (FC) of all infarcted groups versus sham group. The scaling 
of FC value for hierarchical clustering at day 2 post-MI excluded the exaggerated FCs 
from the outliers found in PAG-treated group (Figure 3.12A) for better representative of 
the miRNA expression profiles. As seen from hierarchical clustering plot (Figure 3.13A), 
many of detected miRNAs were down-regulated at day 2 post-MI. Hierarchical clustering 
analyses of infarcted groups versus healthy sham at day 2 post-MI showed that miRNA 
profiles of untreated (MI), placebo- and GYY-treated group were clustered together 
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whereas miRNA profiles of PAG-treated group was different from the other infarcted 
group (Figure 3.13A). Although clustered together, miRNA profiles of GYY-treated 
group displayed different miRNAs distribution pattern compared to MI and placebo-
treated group. Compared to day 2 post-MI, many of the detected miRNAs were up-
regulated at late phases following MI (day 7 post-MI; Figure 3.13B). Hierarchical 
clustering analyses of infarcted groups versus healthy sham at day 7 post-MI 
demonstrated that MI and PAG groups were clustered together, followed by clustering 
with GYY group, whereas miRNA profiles of placebo-treated group was different 
compared to all other infarcted groups (Figure 3.13B). Nonetheless, miRNA profiles of 
GYY-treated group displayed different miRNAs distribution compared to other infarcted 
groups at day 7 post-MI. These results demonstrated that GYY treatment affected the 












Figure 3.13 miRNAs expression profiles in the acute and late phases following MI. 
Hierarchical clustering plot (heatmap) with average linkage and Euclidean distance 
metric of fold change of miRNAs in pooled samples of heart tissue of all infarcted groups 
versus sham at  (A) day 2 and (B) day 7 post-MI (n=1 pooled sample/group/time-point). 
Highlighted red boxes represent clusters of miRNAs that are possibly distinct for GYY-
treated group. The up-regulated miRNAs are shown in red and down-regulated miRNAs 
are shown in green.  
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3.7.2 QPCR validation demonstrated distinct expression of miR-31 upon GYY 
treatment 
Thirteen dysregulated miRNAs that were highly conserved in human, mouse and rat were 
chosen for validation using quantitative stem-loop real time-PCR on individual samples 
(n=6/group) by taking into consideration of the following criteria: miRNAs that had FC 
>1.2 or FC<-1.2 in at least one group, or were distinct in GYY-treated group, or were 
expressed differently at both time-points (Figure 3.14).  
 
Figure 3.14 Thirteen dysregulated miRNAs for QPCR validation. Hierarchical 
clustering plot (heatmap) of fold change of thirteen dysregulated miRNAs expression in 
pooled samples of heart tissue of all infarcted groups versus sham chosen for QPCR 
validation in (A) day 2 and (B) day 7 post-MI (n=1 pooled sample/group/time-point). The 
up-regulated miRNAs are shown in red and down-regulated miRNAs are shown in green. 
 
We then validated these miRNAs with QPCR. At both time-points of evaluation, 
expression of seven miRNAs (miR-31, miR-221, miR-193, miR-206, miR-214, miR-222 
and miR-30d) could be validated in all groups (Figure 3.15) i.e. showed similar 
74 
 
expression pattern (either up-regulated or down-regulated) to the array data (Figure 
3.14). miR-31 expression in the non GYY infarcted groups was significantly elevated 
relative to sham group at day 2 post-MI (8.69±2.64, P<0.05; 8.08±2.20, P<0.05; 
11.75±1.17, P<0.001; Figure 3.15A) and markedly increased by 20-30 fold relative to 
sham at day 7 post-MI (32.14±2.95, P<0.0001; 30.38±3.39, P<0.0001; 21.25±5.41, 
P<0.01; Figure 3.15A). miR-31 expression of untreated MI and placebo-treated group 
was also significantly increased in a time dependent manner  from day 2 to day 7 post-MI 
(P<0.0001; Figure 3.15A). Notably, the GYY-treated group displayed significantly 
distinct miR-31 expression (Figure 3.15A). Although expression of miR-31 in the GYY-
treated group appeared somewhat  elevated compared to sham at both time-points 
(7.42±1.02 at day 2 and 13.76±2.06 at day 7 ), these elevations were not statistically 
significant (Figure 3.15A) and were far less pronounced than observed in the other 
infarct groups. miR-31 expression in GYY-treated rats was significantly repressed 
compared to MI and placebo-treated rats at day 7 (P<0.01 and P<0.0.5; Figure 3.15A).  
Hence, GYY treatment suppressed the increase in miR-31 that resulted from infarction. 
At day 2 post-MI, expression of mir-221 was significantly up-regulated in PAG-treated 
group relative to sham (P<0.01; Figure 3.15B) while the expression in the remaining 
groups did not differ significantly relative to the sham group. At day 7 post-MI, the 
expression level of miR-221 in GYY-treated rats (2.85±0.30), was not statistically 
significant when compared to sham rats; whereas, it was significantly increased in other 
infarcted groups (3.52±0.66, P<0.01; 4.49±0.43, P<0.0001; 3.09±0.46, P<0.05). There 
were also no significant changes in miR-221 level in GYY group when compared to MI 
or placebo group (Figure 3.15B). Likewise, no significant difference could be observed 
in the expression of miR-193 among all groups at day 2 post-MI, with significance only 
seen in MI group relative to sham at day 7 post-MI (P<0.05; Figure 3.15C). 
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Furthermore, presence of GYY did not alter miR-193 expression when compared to MI, 
placebo and PAG-treated group (Figure 3.15C). The expression profile of miR-206 
(Figure 3.15D) and miR-30d (Figure 3.15E) exhibited similar observation. Their 
expression were significantly down-regulated (relative to sham) at day 2 post-MI among 
all infarcted groups while their expression at day 7 post-MI went back to baseline (similar 
to that of sham group) with the exception of miR-206 expression in placebo-treated group 
(Figure 3.15D and E). Although not significant, the expression of miR-206 at day 2 
post-MI was not as suppressed in GYY-treated group compared to the other infarcted 
groups (Figure 3.15D). On the other hand, miR-222 expression remained elevated at 
both time-point of evaluation and GYY treatment did not change the expression level 
when compared to MI-, placebo- and PAG-treated group (Figure 3.15F). Expression of 
miR-214 at day 2 post-MI was comparable among groups and it was elevated 
significantly in MI and placebo-treated group at day 7 post-MI relative to sham (P<0.05 
and P<0.001; Figure 3.15G). In addition, miR-214 expression in GYY-treated group at 
day 7 post-MI was not statistically different to its expression at day 2 post-MI; whereas, 





Figure 3.15 Validation of seven miRNAs by QPCR for both time-points of 




Figure 3.15 Validation of seven miRNAs by QPCR for both time-points of 
evaluation. Expression of (A) miR-31, (B) miR-221, (C) miR-193, (D) miR-206, (E) 
miR-30d, (F) miR-222 and (G) miR-214 in heart tissue of sham, untreated (MI), placebo-
, GYY-, PAG-treated rats validated by QPCR. Array data of each miRNA is presented in 
the table underneath the bar graph. Positive numbers represent up-regulated expression 
relative to sham group. Negative numbers with (-) represent down-regulated expression 
relative to sham group. Values are presented as mean fold change (FC) ± SEM for QPCR 
and FC for miRNAs array data. Group-time interaction statistical significance indicated 
as follows: *a P<0.05 vs. Sham; **a P<0.01 vs. Sham; #a P<0.001 vs. Sham; ##a 
P<0.0001 vs. Sham; *b P<0.05 vs. Day 2; #b P<0.001 vs. Day 2; ##b P<0.0001 vs. Day 




On the other hand, expression of miR-21, miR-195 and miR-223 could only be validated 
in all groups at day 2 post-MI (Figure 3.16 A-C), while the profiles of these miRNAs at 
day 7 post-MI did not match the array data. At day 7 post-MI, contrasting expression 
profile was found in miR-21 expression in MI and GYY-treated group (Figure 3.16A), 
miR-195 expression in GYY-treated group (Figure 3.16B), and miR-223 expression in 
MI group (Figure 3.16C) when compared to miRNA array data, although the expression 
of these three miRNAs could be validated in the remaining groups.  
Similarly, the expression of miR-199a-3p, miR29b and miR-34a could only be validated 
through QPCR in all groups at day 7 post-MI (Figure 3.16D-F). As seen in Figure 
3.16D, expression of miR-199a-3p was only validated in MI group whereas the other 
infarcted groups demonstrated opposite expression compared to miRNA array data at day 
2 post-MI. Contradicting expression pattern was also found at day 2 post-MI in miR-29b 
expression in all groups (Figure 3.16E) and in miR-34a expression in GYY- and PAG-
treated group (Figure 3.16F) when compared to miRNA array data. 
There was no significant change in the expression of miR-199a-3p and miR-34a among 
all groups at day 2 post-MI (Figure 3.16 D and F) while expression of miR195 remained 
unchanged among all groups at day 7 post-MI (Figure 3.16B). The expression level of 
miR-195 and miR-199a-3p in all infarcted groups displayed a bi-phasic expression 
pattern from being down-regulated (relative to sham group) at day 2 post-MI to being up-
regulated (relative to sham group) at day 7 post-MI (Figure 3.16B and D). In addition, 
GYY-treated group had significantly lower expression of miR-199a-3p relative to 
placebo-treated group at day 7 post-MI (P<0.05; Figure 3.16D) which may suggest that 
GYY treatment might contribute to suppress the up-regulation of miR-199a-3p, although 
no significant difference could be seen between GYY and PAG-treated group. Expression 
of miR-21 in all groups remained elevated (relative to sham group) at both time-points of 
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evaluation, yet this expression was only significant in MI- and PAG-treated groups at day 
2 post-MI and in MI- and placebo-treated groups at day 7 post-MI (Figure 3.16A).  
Taken together, these results demonstrated that only miR-31 was distinctively modulated 
by GYY while the expression of other aberrantly expressed miRNAs was comparable to 






Figure 3.16 Validation of six miRNAs by QPCR in either time-point of evaluation. 
Expression of (A) miR-21, (B) miR-195, (C) miR-223, (D) miR-19a-3p, (E) miR-29b 
and (F) miR-34a in heart tissue of sham, untreated (MI), placebo-, GYY-, PAG-treated 
rats validated by QPCR. Array data of each miRNA is presented in the table underneath 
the bar graph. Positive numbers represent up-regulated expression relative to sham group. 
Negative numbers with (-) represent down-regulated expression relative to sham group. 
Values are presented as mean fold change (FC) ± SEM for QPCR and FC for miRNAs 
array data. Group-time interaction statistical significance indicated as follows: *a P<0.05 
vs. Sham; **a P<0.01 vs. Sham; #a P<0.001 vs. Sham; *b P<0.05 vs. Day 2; **b P<0.01 




H2S is emerging as an important endogenous gasotransmitter that protects against 
numerous injurious stimuli through activation of signaling pathways that are protective in 
cardiac injury46, 71, 136. The neurohormonal response is critical in the evolution of MI to 
adverse LV remodeling, and all pharmacotherapies (ARBs, β-adrenoceptors blocker 
therapy, and ACE inhibitors) currently proven to ameliorate adverse remodeling in 
clinical HF operate via neurohormonal pathways137. In this study, the possibility of H2S –
mediated modulation of neurohormonal activation has been raised. In vitro, high 
concentration of H2S inhibited ACE in endothelial cells138 while in vivo, it has also been 
implicated in regulating the renin-angiotensin system by inhibiting degranulation of mast 
cells and blocking thereby renin release in a isoproterenol (ISO)-induced HF model139. In 
addition, various miRNAs have been found to be associated with pathological changes 
after MI121-128. H2S has been reported to up-regulate miR-133a, which inhibited 
cardiomyocyte hypertrophy in an in vitro model140 while in vivo, H2S attenuated 
myocardial injury via induction of miR-21141. The implications of H2S in modulating 
neurohormonal response and miRNAs are critical for a better understanding of potential 
therapeutic role during myocardial injury, as this would provide further insights on the 
cardioprotective effect of H2S and its future application. To date, most of H2S studies in 
the context of cardiac injury have utilized NaHS, as it is commercially available and easy 
to handle. However, NaHS is a very volatile and short-lived donor that might not be 
physiologically relevant to study H2S therapeutic potential in vivo67. In this study, GYY, 
a slow-releasing H2S donor that mimics its endogenous physiological release, was 
employed. The effects of GYY on LV remodeling and function following myocardial 
injury have not been characterized yet. We hypothesized that GYY is cardioprotective in 
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a rat model of myocardial infarction and exerts this effect, in part, through modulation of 
the neurohormonal response and miRNAs. 
The animal model used in this study was a permanent LAD ligation-induced MI model. 
This model is one of the most widely used and standard technique of inducing regional 
injury and subsequent HF in rodents142, 143. It is also a useful model to understand further 
the pathophysiology of post-MI cardiac remodeling due to changes in extracellular matrix 
and neurohormonal activation144-146. In rats, mortality of this model happens within the 
first hour after infraction due to ventricular fibrillation and it ranges between 35-50%147. 
In our study, we observed 10-20% mortality with the highest observed in PAG-treated 
group. PAG has been reported to also inhibit other metabolic processes that could lead to 
possible diuresis and toxic renal effects148 that could explain the slightly higher mortality 
rate observed in this group.  
 
4.1 Modulation of H2S system by GYY  
Exogenous administration of GYY increased plasma H2S levels at both day 2 and 7 post-
MI (Figure 3.1) indicating that dose regimen used in this study was sufficient and 
therefore, therapeutic effects exerted by this treatment were indeed because of increased 
H2S level. Although it has been reported that plasma H2S level in rat model of ISO-
induced myocardial injury was decreased59, in this study however, plasma H2S level in 
untreated infarcted rats and placebo-treated rats were comparable to sham. Apart from the 
difference in animal model, this discrepancy might also be due to difference in the 
method of measuring plasma H2S level. In the above-mentioned study, Geng and 
colleagues measured the endogenous plasma H2S level using methylene blue method. 
Though this method is very common, it has been shown to pose limitation as it measures 
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not only free H2S but also other molecules (sulfide  and hydrosulfide anion)43, 148. In this 
study, we employed fluorimetric-based method which used monobromobimane (MBB) to 
trap free H2S and the resulting dibimane was then separated by HPLC and detected 
through its fluorescence property149. Baseline level of free H2S measured by MBB 
method has been proven to be more physiologically relevant compared to methylene blue 
method40. However, it is important to note that various biological effects of H2S most 
probably happen inside the cell. Thus, H2S measurement either in plasma or in 
homogenized tissue might not reflect its cellular site of action. However, up until now, 
there are no assays that are sensitive, selective and capable to measure real-time 
intracellular H2S43. 
Most endogenously generated H2S is derived from the metabolism of L-cysteine by two 
pyridoxal-5′-phosphate-dependent enzymes: cystathionine β synthase (CBS) and 
cystathionine γ lyase (CSE) which are inhibited by PAG43. CSE is abundantly expressed 
in liver as well as in vascular and non-vascular smooth muscle78, 132. In this study, 
expression of CSE protein was detected in liver tissue from all animal groups and as 
expected, no inter-group difference was apparent at either time-point (Figure 3.2C and 
D). Treatment with PAG significantly reduced H2S synthesizing activity of CSE as 
observed through the exogenous addition of L-cysteine in liver homogenates (Figure 
3.2E). Thus, this indicated that the dose regimen used was effective in inhibiting tissue 
CSE activity despite not detecting reduction in plasma H2S level.  
 
4.2 Modulation of early neurohormonal response by GYY is cardioprotective  
GYY increased the expression and release of ANP and BNP; importantly, plasma ANP 
concentration increased several fold higher compared to those of comparator groups in 
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the late phase after MI (Figure 3.7). The main stimulus for NP release is myocardial 
stretch95, and yet, the highest expression and release of NPs was observed in GYY-treated 
group that had the best preserved hearts with lowest intra-cardiac pressures. This pattern 
of elevated plasma NP in the presence of preserved LV structure, function and intra-
cardiac pressures is striking and unusual. In addition, we also observed that ANP mRNA 
level upon GYY treatment increased several fold higher relative to other comparator 
groups in the early phase after MI (Figure 3.8A). These results are strongly suggestive of 
a specific and direct effect by the H2S donor to enhance NP expression and secretion. 
Increased in ANP mRNA expression upon H2S treatment in both phenylephrine (PE)-
induced hypertrophied and non-hypertrophied cardiomyocytes has also been reported 
previously140. Interestingly, mRNA level of NPR3, the receptor clearance, was found to 
be not as repressed in GYY group at day 2 post-MI  though this effect was abolished at 
day 7 post-MI (Figure 3.8G and H). Although the implications of this result were not 
clear, it may be possible that ANP clearance through NPR3 contributed to the level of 
plasma ANP in GYY group which was not as elevated at day 2 post-MI. The effect of 
GYY on NPR3 needs to be further investigated. 
A growing body of evidence supports a role for ANP and BNP as cardioprotective 
hormones despite being used as diagnostic marker to monitor severity of hypertrophy and 
HF in clinical settings. They counteract the cardiac hypertrophic effects of Ang 2150-152. 
Both ANP and BNP affect multiple neurohormonal (including RAAS system, endothelin 
and sympathetic nerve activity) and anti-proliferative pathways involved in pathological 
LV remodeling and progression to HF153. Genetic abrogation of ANP or NPR-1 resulted 
in cardiac hypertrophy and fibrosis97, 154, while ANP deficiency in mice with dilated 
cardiomyopathy led to further impairment of LV systolic function155. Infusion of ANP in 
dogs following LAD ligation had significantly lower LVEDP and less severity of 
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myocardial injury compared to placebo control156. In rats, treatment with recombinant 
BNP immediately after coronary ligation decreased infarct size157 and enhanced cardiac 
contractility158. Short-term constant infusion of BNP conserved LV systolic function and 
dimension, and prevented the development of systolic heart failure after persistent 
ischemic injury in dogs subjected to repetitive coronary embolization159. Whereas, long-
term administration of BNP after MI for eight weeks in rats attenuated ventricular 
remodeling and improved cardiac function and this effect was associated with the 
inhibition of transforming growth factor β1 (TGF-β1)/ mothers against decapentaplegic 
homolog 2 (Smad2) pathway160. In a clinical study, early administration of human 
recombinant BNP, nesiritide, after MI increased plasma cGMP and C-type natriuretic 
peptide while decreasing other cardiac peptides with a neutral outcome on renal function 
and an inclination towards attenuation of LV remodeling161. In a clinical study, 
administration of human atrial natriuretic peptide (hANP, carperitide) prevented LV 
remodeling and preserved LV function162 and increased collateral blood flow163 in MI 
patients after PCI. Infusion of hANP before MI provided cardioprotection probably 
through a NO-PKC dependent pathway followed by activation of mitochondrial KATP 
channel164. hANP also exhibited an antioxidant action, which may ameliorate ischemia-
reperfusion injury and  limit infarct size, increased collateral blood flow and decreased 
LVEDP165, 166. Moreover, activation of NPR1 upon binding of ANP or BNP generated an 
increase in its second messenger, cGMP, which was clearly increased in parallel to 
plasma ANP and BNP in our study (Figure 3.10A). cGMP mediates natriuresis and 
inhibition of renin and aldosterone, attenuates hypertrophy and, adverse remodeling, as 
well as promotes angiogenesis105, 106, 152, 155, although in our results, plasma renin activity 
and aldosterone remained unchanged. Given these promising actions, the NP system 
serves as an important compensatory mechanism against deleterious neurohormonal 
activation following MI, and an enhanced early endogenous NP response is a plausible 
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contributor to the cardioprotection offered by GYY. However, further studies are 
necessary to investigate the exact mechanism of GYY-induced ANP and BNP activation 
and long-term effect of GYY on ANP and BNP activation and consequence results of 
these sustained activations to the heart function.  
In addition, GYY treatment had an effect on apelin expression, an adipokine that binds to 
APJ, which has been reported as cadioprotective in acute myocardial ischemia135. Cardiac 
apelin mRNA level was up-regulated in GYY-treated rats compared to PAG treatment at 
day 2 post-injury, while suppressed in infarcted groups relative to sham group (Figure 
3.9D). Likewise, cardiac apelin was up-regulated in the GYY rats relative to all infarcted 
groups at day 7 post-injury. In parallel, APJ mRNA level was up-regulated in animals 
treated with GYY compared to PAG-treated animals (Figure 3.9E). Consistently, it has 
been reported that apelin level following LAD ligation was reduced in the infarct and 
peri-infarct regions at 1 day post-MI which persevered up to 7 days post-MI; whereas 
APJ, was up-regulated 1 day post- MI followed by down-regulation at day 7167. Apelin 
has lasting cardioprotective effects after MI through reduction of cardiac tissue damage 
and lipid peroxidation with augmentation of NO production135. Apelin also prevented 
TGF β-induced activation of cardiac fibroblasts and collagen production in vitro168. 
Administration of apelin-12 peptide during reperfusion following ischemia in rats limited 
infarct size and decreased post-ischemic cardiomyocyte membrane damage through NO-
dependent mechanisms169, while treatment with apelin-13 promoted angiogenesis in 
infarcted hearts170 and improved cardiac repair post-MI171. Apelin treatment also 
increased cardiac contractility and angiotensin converting enzyme-2 (ACE-2) level in 
APJ-deficient mice and a coupling of the RAAS and apelin system via ACE-2 has been 
suggested172. Hence, an H2S-induced increase in endogenous cardiac apelin could also 
have contributed to the cardioprotective effect observed in this study. 
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4.3 cGMP-dependent and -independent signal transduction may mediate the 
therapeutic effect of GYY  
Previous reports have shown that H2S mediated improvement of survival and attenuation 
of cardiac dysfunction and infarct size in infarcted rodents66, 173. In our study, treatment 
with GYY limited final infarct size (as assessed by LV scar dimensions), attenuated 
adverse remodeling and provided sustained preservation of cardiac structure and function 
following MI in a rat model, as evidenced by echocardiography (Figure 3.3 and 3.4), 
hemodynamic measurements (Table 3.1) and morphometric studies (Figure 3.5). 
Furthermore, GYY preserved LV end-systolic and diastolic volumes, LV end-diastolic 
pressure and LV ejection fraction (Figure 3.4), all of which are reliable indicators of 
cardiac function and accepted predictors of adverse outcomes in clinical practice. 
Furthermore, our results demonstrated that GYY promoted angiogenesis within the LV 
scar following ischemic injury (Figure 3.6). Angiogenesis is one of the vital mechanisms 
to heal the injured myocardium after infarction27.     
We found that GYY treatment increased cGKIα protein level at day 2 post-MI (Figure 
3.10C and D). However, increased in cGKIα protein level does not represent the 
catalytic activity of cGKI. Therefore, the implication of this result is not clear as we did 
not perform an assay to measure the catalytic activity of cGKI which could provide a 
better correlation with our results showing an increase of plasma cGMP at day 7 post-MI. 
Nonetheless, the early increased of cardiac cGKIα protein, in parallel with increased of 
plasma cGMP may have played a role in the pro-angiogenic effect observed in GYY-
treated animals, since in vascular endothelial cells, cGMP-cGK signaling modulates cell 
migration, motility, and proliferation, all of which are essential for angiogenesis95. H2S 
was reported to promote angiogenesis under ischemic conditions both in vitro and in vivo 
and could elicit protective effects through activation of VEGF-Akt-eNOS-NO-cGMP 
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signaling pathway, while elevating NO bioavailability in pressure-overload induced HF 
in rodents174. We found post-MI down-regulation of cardiac VEGF-A mRNA in both 
infarct and peri-infarct tissues from all groups relative to sham group; yet, mRNA level in 
GYY-treated animals were less suppressed than in the other infarcted groups and showed 
a trend towards higher protein expression  post-MI (Figure 3.11). H2S and NO cross-talk 
have been shown to promote angiogenesis through the cGMP-cGK signaling pathway175, 
176. Accordingly, we detected increases in plasma NO and cGMP in GYY-treated rats 
post-MI. Since ANP and BNP levels were also significantly increased in GYY-treated 
animals at the same time-point, this suggests that the rise observed in plasma cGMP 
could reflect both increased plasma NPs and NO (Figure 3.10A and B). In addition, 
ANP and BNP have been demonstrated to regulate angiogenesis in the heart and skeletal 
muscle through cGKI106, 109. GYY-induced angiogenesis may also occur through cGK-
independent pathways. Notably, GYY has been shown to induce a minor increase in 
cGMP compared to NaHS in isolated aortic ring experiments and promotes 
vasorelaxation through a cGK-independent pathway177. In addition, NPs could act on 
vascular tissue through cGMP regulated phosphodiesterases (PDEs)178  and cyclic 
nucleotide-gated ion channels (CNGs)179. PDEs are involved in endothelial cell 
migration, proliferation and angiogenesis180, while CNGs are Ca2+-permeable non-
selective cation channels that open upon adenosine 3'-5'-cyclic monophosphate (cAMP) 
or cGMP binding181. CNGA2, a CNG subunit expressed in human and rat vascular 
tissues, was activated by ANP more readily than NO in CNGA2-expressing vascular 
smooth muscle cells182. Furthermore, increased expression of apelin in our study at day 7 
(Figure 3.9 D) might be associated with increase in plasma cGMP at the same time-point 
as apelin secretion has been reported to be regulated through cAMP and cGMP 
dependent pathways in the adipocytes183. Thus, it is possible that GYY plays a role in 
angiogenesis and arteriogenesis through cGMP-cGK downstream signaling or cGMP-
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cGK-independent pathways during cardiac ischemic injury and this warrants further 
investigation.  
Cardiac mitochondrial protection has been implicated as one of the mechanisms behind 
NaHS cardioprotection through increased expression of anti-apoptotic BCL-2, decreased 
expression of pro-apoptotic BAX and caspase-3 and reduction of cytochrome c protein 
leakage from mitochondria to cytoplasm173. NaHS, administered 5mins before MI and 
60mins after MI in mice, was shown to improve survival by preserving LV function and 
reducing infarct size, through the regulation of BAX/BCL-2 pathway and anti-
inflammatory response66. We have found that BCL-2 mRNA expression was increased 
and there was a trend towards increased BCL-2 protein in GYY-treated rats compared to 
PAG-treated (Figure 3.11). Discrepancies between mRNA and protein expression in this 
study could be due to a higher protein degradation/lower stability secondary pathology. 
Another possible explanation is that, in this study, we have evaluated tissues only from 
the infarct and peri-infarct area and did not incorporate the remote healthy myocardium.  
 
4.4 Modulation of miRNAs by GYY 
Since normalization in analyzing miRNA array data is important to eliminate variations 
that arise from technical and sample variations, we performed global quantile 
normalization method that has been reported to work best and more robust in reducing 
difference in miRNAs expression values. This method adjusts the differential bias across 
the scale of expression values184, 185.  
Seven out of thirteen selected dysregulated miRNAs in heart tissue after myocardial 
infarction namely: miR-31, miR-221, miR-193, miR-206, miR-214, miR-222 and miR-
30d from the miRNA array data could be validated (showed similar pattern of up-
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regulation or down-regulation) through QPCR for both time-points (Figure 3.15). 
miRNAs from day 2 post-MI (miR-199a-3p, miR-29b and miR-34a) and day 7 post-MI 
(miR-21, miR-195 and miR-223) that could not be validated were detected in QPCR with 
opposite expression from miRNA array data (Figure 3.16). In the microarray platform, 
signals obtained depend on hybridization temperature, specificity and length of the 
probe186, 187. As a result, binding affinities vary among miRNAs and there could be false 
positive results. Thus, miRNA array should only be used to seek out possible unique 
miRNAs and alone should not be used to make quantitative statements and needs to be 
validated with other platform. Stem-loop QPCR quantification of miRNAs expression 
used in this study has been commonly used to validate miRNA array data as it has high 
specificity187, 188. Besides, our miRNA array was performed with pooled samples of three 
whereas QPCR was performed on six individual samples. Therefore, results obtained 
from QPCR are more reliable for quantitative measurements of miRNAs expression. 
Post-ischemic treatment with GYY suppressed the expression of miR-31 in the late phase 
after MI whereas the other infarcted groups expressed 20-30 folds higher relative to sham 
group by day 7 post-MI (Figure 3.15A). miR-31 has been shown to target myogenic 
determination gene, Myf5, thereby repressing myogenesis189. Through Islet-1, miR-31 
regulates cardiac fibrogenic epithelial-to-mesenchymal transition (EMT)190. Evidence 
suggests that epicardial mesothelial cells undergo fibrogenic EMT upon cardiac stress to 
generate myofibroblast-like cells191-193 that contribute to the development of fibrosis194. 
miR-31 also directly binds to cellular repressor of E1A-stimulated genes that plays a vital 
role in modulating vascular smooth muscle cells (VSMCs) phenotype by retaining these 
cells in the differentiated mature phenotype state195. Restenosis after PCI is linked to 
VSMC phenotype modulation, whereby VSCMs de-differentiate from a contractile to 
synthetic phenotype after vascular injury196. In parallel to this, serum miR-31 level is 
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elevated in coronary artery disease (CAD) patients with restenosis compared to CAD 
patients without restenosis and to healthy controls, suggesting that miR-31 may be a 
potential biomarker in diseases concerning VSMC phenotypic modulation195. In addition, 
a parallel study carried out by our group has also demonstrated that miR-31 is deleterious 
to cardiac function and its inhibition after MI in vivo ameliorates cardiac dysfunction 
(data not shown- manuscript in preparation). Using target prediction database, 
miRWalk197, miR-31 is predicted to target cardiac troponin T type 2 (TNNT2) and E2 
factor transcription factor 6 (E2F6) genes in the 3’UTR. TNNT2 plays an important role 
in the regulation of contractile function198. Mutations in this gene are involved in the 
progression of molecular and structural ventricular remodeling199 and associated with 
familial hypertrophic cardiomyopathy as well as with dilated cardiomyopathy200. E2F6 
plays a role as a repressor of gene transcription during cell cycle progression and 
growth,201 and it has been validated as target of miR-31 in the highly malignant prostate 
cancer cell line and over-expression of E2F6 contributes to apoptosis resistance in benign 
prostate cancer cell line202. Interestingly, during myocyte hypertrophy, E2F6 protein is 
significantly up-regulated and this is in parallel with the re-entry of myocytes to the cell 
cycle. In addition, knocking down E2F6 gene decreases viability of cultured neonatal 
myocytes suggesting that E2F6 is possibly involved in myocardial regeneration203.    
We also found that miR-221 was not so elevated in GYY treated-rats 7 days after MI in 
comparison to the other infarcted groups (Figure 3.15B). This finding is in agreement 
with a recent report that demonstrated inhibition of miR-221 by organosulfur garlic 
compound, DATS, in human EPCs in vitro. Furthermore, inhibition of miR-221 causes 
up-regulation of vasculogenic c-kit protein, promoting thereby neovasculogenesis204. Up-
regulation of miR-221 suppresses the expression of c-kit protein and this obstructs the 
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angiogenesis process in human endothelial cells in vitro205. Likewise, miR-221 level is 
significantly higher in EPCs from patients with CAD compared to healthy subjects206.  
Moreover, based on miRWalk predictions, both miR-31 and miR-221 possibly target 
apelin in the 3’UTR. Since miRNAs repress their targets, it is important to note that 
suppression of miR-31 and possibly miR-221 by GYY in parallel with the increase in 
apelin expression observed in our study strongly suggest this association. However, direct 
interaction between miR-31 and miR-221 with apelin needs to be further investigated. 
Taken together, modulation of miRNAs expression, namely miR-31 and possibly miR-
221, may contribute to the observed cardioprotective and pro-angiogenic effects of GYY. 
GYY-treated rats also expressed slightly different expression of miR-206, miR-214 and 
miR-199a-3p compared to other infarcted groups (Figure 3.15 and 3.16). These miRNAs 
have been associated with cardiac injury. miR-206 is expressed specifically in muscle 
and plays a role in myogenesis207, 208. It suppresses hypertrophy in myogenic cells through 
inhibition of histone deacetylase 4 (HDAC4) in vitro209. miR-206 also targets tissue 
inhibitor of metalloproteinase 3 (TIMP-3) and it contributes to the high mobility group 
box-1 protein (HMGB1)-mediated attenuation of cardiac remodeling after MI210. miR-
214 is up-regulated in response to ischemic injury and heart failure211. It protects the heart 
against ischemia reperfusion injury by regulating calcium influx and cell death through 
sodium/calcium exchanger 1 in vivo212. Inhibition of miR-214 suppresses proliferation 
and differentiation of mouse myoblast cell line (C2C12)213. Moreover, miR-214 also 
regulates angiogenesis by targeting Quaking, a key regulator of vascular development 
and remodeling, as well as decreasing angiogenic growth factor release214. Likewise, 
miR-199a-3p is up-regulated four days after pulmonary artery constriction in the right 
ventricle hypertrophy and failure model and it is associated with cardiomyocyte size and 
fibrosis215. In contrast to inhibition of miR-214, inhibiting miR-199a-3p with antisense 
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oligonucleotides induces C2C12 differentiation and myotube hypertrophy by targeting 
insulin-like growth factor 1 (IGF-1), mTOR and ribosomal protein S6 kinase (RPS6KA6) 
in the iGF-1/AKT/mTOR signaling pathway216. Further studies are needed to investigate 
the contribution of miR-206, miR-214 and miR-199a-3p to the GYY-mediated 
cardioprotective effect.  
Although it has been reported that H2S induces miR-133a in vitro140, we did not observe 
it in our in vivo study (Appendix 1 and 2). We also did not find increase of miR-21 in 
GYY-treated group compared to placebo group (Figure 3.16A) as reported by Toldo and 
colleagues141. This might be due to the difference in animal model, H2S donor used, and 
the time-point of miR-21 measurement. In their study, Toldo and colleagues measured 
the level of miR-21 one hour after sodium sulfide or saline administration and before the 
ischemia/reperfusion injury while we measured the level of miR-21 2 days and 7 days 
after MI and treatment.  
 
4.5 Limitations of H2S donors including GYY in clinical application 
H2S donors including GYY are potential clinical therapeutic agents in cardiovascular 
diseases. However, there are some limitations of these donors that need to be addressed 
before they can be used clinically. One of the major challenges is to develop an accurate 
and non-invasive method of H2S measurement in plasma, as well as at the cellular and in 
intracellular compartments217. This would allow to determining the efficacy of H2S 
donors after its administration in delivering H2S to intracellular targets and to monitor 
any potentially toxic high levels. Another limitation is that the byproducts that are 
produced after H2S release from these donors including GYY are still unclear218. It is 
important to identify these products and investigate their biological activities to prevent 
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any future side effects for chronic clinical application that could potentially arise, such as 
hypotension and excessive angiogenesis. In the future, a targeted delivery of H2S donors 
to the heart might help to circumvent these potential systemic side effects.   
In conclusion, we demonstrated that post-ischemic therapeutic intervention with the 
slow-releasing H2S donor, GYY, preserves cardiac function and attenuates adverse 
remodeling during the acute and late phases following MI. The mechanisms involved 
behind GYY cardioprotection may include a specific enhancement of the beneficial 
natriuretic peptide response to cardiac stress and suppression of miRNAs deleterious to 
cardiac function with associated post-ischemic promotion of pro-angiogenesis, anti-












5. FUTURE PERSPECTIVES 
This study raises the novel possibility that GYY may exert cardioprotective actions in 
vivo through H2S-induced natriuretic peptide activation and H2S-mediated miRNAs 
modulation. Exogenous recombinant NPs have been used therapeutically in clinical MI 
and acute HF with mixed results219-221 and further prospective studies are necessary to 
address the controversy about safety of these recombinant drugs87, 113. Therefore, 
definition of long-term effects of GYY administration following ischemic injury on NPs 
activation need to be further investigated. It is also important to study the exact 
mechanisms behind NP activation. Since GYY up-regulated mRNA expression of ANP 
and prevented down-regulation of NPR3, it will be interesting to know if H2S can 
regulate the promoter of the ANP and NPR3 gene to regulate their mRNA biosynthesis 
and degradation. GYY could also modulate ANP at the protein level since plasma ANP 
was found to be several folds higher at the late phase post-MI. In addition, protein level 
of cGKIα was also increased upon GYY treatment. A recent study has suggested that H2S 
signals through proteins s-sulfhydration (converting cysteine –SH groups to –SSH) and 
this process augments the activity of the targeted proteins45. Following that, various 
studies have reported protein targets of s-sulfhydration including ion channels222, 223, p65 
subunit of NF-κB that is involved in apoptosis pathway224 and phospholamban that is 
involved in cardiac contractility and relaxation225. Based on these studies, post-translation 
modification by H2S, i.e. s-sulfhydration, could possibly play a role on ANP and cGKIα 
at protein level. Therefore, s-sulfhydration study using mass-spectometry platform can be 
used to identify specifically targets of GYY including NPs, cGKIα and apelin that 
contribute to its cardioprotective effect. Additionally, catalytic activity of cGKIα and 
PDE can be performed in upon GYY treatment to determine its effect on the downstream 
effectors of cGMP. 
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Moreover, GYY also modulated two of the dysregulated miRNAs that are predicted to 
target apelin. It will be necessary to confirm the direct binding of apelin to miR-31 or 
miR-221 using gene reporter assay. Validation of other possible predicted targets of miR-
31 (including TNNT2) and miR-221 that may play a role in angiogenesis, fibrosis and 
apoptosis will also be of particular interest to further understand the mechanism of 
observed therapeutic effect of H2S-mediated miRNAs modulation. Alternatively, 
modulating expression of miR-31 and miR-221 expression with mimics or inhibitors and 
subsequently evaluating the downstream effect on target genes can also be carried out to 
confirm the presence of direct binding. Additionally, the role of miR-206, miR-214 and 
miR-199a-3p in GYY-treated rats needs to be further investigated. Validation of targets 
of these miRNAs that may contribute to GYY-mediated cardioprotective effect is also 
necessary. Furthermore, there may be other miRNAs that are distinctively modulated by 
GYY that have not been validated. Thus, validation of these miRNAs and their 
downstream targets is also necessary and is underway. 
In addition to mechanistic studies, it will be of particular clinical relevance to evaluate 
the effect of delayed treatment of GYY after early LV remodeling and dysfunction has 
happened. Immediate treatment (30min) after myocardial injury might not be clinically 
applicable, as in most cases, patients who have heart attack do not receive treatment 
within that short time frame following the ischemic event. Thus, it is necessary to 
evaluate whether the cardioprotective effect of GYY can still be observed when its 
administration is delayed. In addition, it is also important to evaluate the effect of GYY 
in the chronic (long-term) setting and investigate its effect on HF. Moreover, combination 
therapy of GYY with inhibitors of miR-31 or miR-221 can be administered after MI to 
obtain an enhanced synergistic cardioprotective effect. It is important to note, however, 
that each miRNA may target hundreds of genes; thus, off-target effects should be taken 
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into careful consideration when one or both of miRNAs is/are inhibited in vivo. Lastly, 
the effect of H2S deficiency on cardiac function and remodeling can be assessed using in 
vitro and in vivo models of myocardial injury in mice with CSE knockout/ 
overexpression.  Importantly, these models might reveal whether slow H2S release by 
GYY may really mimic the endogenous H2S release pattern in physiological conditions 
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Appendix 1.  miRNA array data of infarcted untreated rats (MI), infarcted placebo-
, GYY-, and PAG- treated rats vs. sham at 2 days after MI 




























rno-let-7a -1.46 -1.73 -1.78 -1.64 rno-miR-24-1* -1.04 -1.07 -1.49 -1.11 
rno-let-7b -1.25 -1.38 -2.04 -1.64 rno-miR-24-2* 1.01 -1.15 -1.28 -1.07 
rno-let-7c -1.46 -1.46 -2.39 -1.66 rno-miR-25 -1.11 -1.22 1.42 1.07 
rno-let-7d -1.25 -1.55 -1.37 -1.11 rno-miR-26a -1.11 -1.28 -1.49 -1.21 
rno-let-7e -1.00 1.24 1.08 -1.03 rno-miR-26b 1.29 1.15 1.24 1.29 
rno-let-7f 1.23 -1.04 -1.26 1.09 rno-miR-27a -1.00 1.07 2.00 1.87 
rno-let-7i -1.09 -1.06 -1.32 -1.00 rno-miR-27b 1.39 -1.14 1.56 1.23 
rno-miR-1 -1.07 -1.07 1.00 1.00 rno-miR-28 -1.46 -1.46 -1.57 -1.43 
rno-miR-100 1.04 -1.46 -1.25 1.19 rno-miR-290 -1.12 1.07 1.16 -1.00 
rno-miR-101b -1.30 -1.36 -1.30 -1.07 rno-miR-291a-3p -1.71 -1.39 -1.62 -1.17 
rno-miR-103 -1.06 -1.12 -1.40 -1.08 rno-miR-29a -1.02 -1.01 -1.01 -1.01 
rno-miR-106b -1.01 1.06 -1.35 -1.21 rno-miR-29a* -1.10 -1.31 -1.26 1.11 
rno-miR-107 1.25 1.14 1.65 1.65 rno-miR-29b 1.23 1.68 3.10 2.80 
rno-miR-10a-5p 1.48 -1.35 1.30 1.07 rno-miR-29c 1.42 1.04 1.42 -3.00 
rno-miR-125a-5p -1.20 -1.47 -1.60 -1.39 rno-miR-300-5p -1.15 -1.15 -1.15 -1.23 
rno-miR-125b-3p -1.41 1.67 1.08 1.29 rno-miR-301a -1.00 -1.02 -1.38 -10.27 
rno-miR-125b-5p -1.36 -1.15 -1.46 -1.19 rno-miR-30b-3p 1.33 1.19 1.12 -1.19 
rno-miR-126 1.09 1.15 -1.00 1.03 rno-miR-30b-5p 1.06 1.02 -1.05 1.02 
rno-miR-126* -1.37 -1.23 1.10 1.10 rno-miR-30c 1.06 -1.00 1.06 -205.23 
rno-miR-129 -1.13 1.02 -1.04 -1.04 rno-miR-30d -1.28 -1.64 -1.99 -1.37 
rno-miR-129* 1.20 -1.01 -1.67 1.81 rno-miR-30e -1.74 -1.57 -1.41 -62.81 
rno-miR-130a -1.11 -1.21 -1.48 -1.11 rno-miR-30e* -1.18 -1.62 -2.06 4.12 
rno-miR-133a 1.21 -1.07 -1.00 1.28 rno-miR-31 9.09 23.04 15.82 13.61 
rno-miR-133b 1.09 -2.34 -1.86 -1.22 rno-miR-32 1.46 1.30 1.57 -1.20 
rno-miR-138* -2.11 -1.81 -2.11 -1.51 rno-miR-320 1.13 -1.09 -1.13 -8.94 
rno-miR-140 -1.27 -1.14 -1.05 1.15 rno-miR-322 -1.08 -1.38 -1.08 1.08 
rno-miR-140* -1.03 -1.08 -1.25 1.06 rno-miR-329 -1.18 1.04 -1.37 1.15 
rno-miR-142-3p 2.17 3.65 4.33 1.54 rno-miR-331 1.05 -1.55 -1.50 1.24 
rno-miR-142-5p 1.80 2.87 3.00 1.39 rno-miR-335 -1.31 -1.15 -2.10 -1.15 
rno-miR-144 1.76 -1.04 2.13 -1.60 rno-miR-336 -2.47 -1.84 -2.05 -1.00 
rno-miR-145 -1.08 -1.36 1.20 1.28 rno-miR-338 1.28 -1.59 1.19 -5.65 
rno-miR-146a 1.12 -1.06 -1.29 -1.06 rno-miR-339-5p 1.23 1.16 1.25 -5.98 
rno-miR-146b 1.40 1.54 1.25 1.16 rno-miR-342-3p -1.29 -1.39 -1.62 -55.96 
rno-miR-148b-3p -1.11 -1.33 -1.60 -1.39 rno-miR-347 -2.86 -1.70 -1.56 -1.10 
rno-miR-150 1.33 -1.13 -2.19 1.08 rno-miR-34a 1.27 1.72 1.42 -1.47 
rno-miR-151 -1.13 -1.28 -1.47 -1.18 rno-miR-34c* -1.13 -1.10 -1.13 1.29 
rno-miR-152 -1.22 -1.24 -1.37 -1.17 rno-miR-350 1.01 -1.08 -1.79 -1.15 
rno-miR-15b 1.21 1.45 1.37 -1.04 rno-miR-351 -1.14 -1.18 1.04 -1.50 
rno-miR-16 1.60 2.14 2.14 2.14 rno-miR-352 1.02 -1.95 -1.17 -1.45 
rno-miR-17 1.36 1.59 1.68 -1.03 rno-miR-361 1.06 1.15 -1.14 -10.27 
rno-miR-181a -1.36 -1.78 -1.14 1.05 rno-miR-365 1.01 -1.00 1.39 -623.29 
rno-miR-181b 1.09 -1.07 -1.00 -1.27 rno-miR-370 1.53 1.51 -1.44 1.51 
rno-miR-184 -1.59 -1.35 -1.00 -1.11 rno-miR-374 1.22 -1.22 1.42 -4.15 
rno-miR-185 -1.10 -1.46 -1.66 -1.19 rno-miR-378 -1.22 -1.37 -1.79 -6767.54 
rno-miR-186 -1.19 -1.38 -1.38 -1.15 rno-miR-378* -1.36 -2.05 -2.38 63.92 
rno-miR-190 -1.33 -1.58 -1.96 -1.09 rno-miR-382* -1.24 1.08 -1.37 1.24 
rno-miR-191 -1.00 -1.15 -1.43 -1.28 rno-miR-423 -1.11 -1.00 1.02 1.11 
rno-miR-193 2.18 3.42 2.18 1.72 rno-miR-434 -1.97 1.08 1.16 1.10 
rno-miR-195 -1.00 -1.23 -1.93 -1.11 rno-miR-451 -1.35 -1.50 1.35 -2.18 
rno-miR-196a* -1.61 -1.07 -1.42 1.04 rno-miR-466c 1.74 1.65 1.65 -1.09 
rno-miR-199a-3p -1.06 1.51 1.41 1.21 rno-miR-487b -1.41 1.35 1.31 -1.00 
rno-miR-199a-5p 1.08 1.23 1.85 1.05 rno-miR-494 -1.00 1.26 1.26 1.32 
rno-miR-19a 1.17 1.53 2.58 1.21 rno-miR-497 1.12 -1.54 -1.08 -1.08 
rno-miR-19b 1.19 1.22 2.56 1.53 rno-miR-499 -1.19 -1.57 -2.06 -1.57 
rno-miR-203 -1.19 1.13 -1.46 -1.23 rno-miR-500 1.32 1.19 1.19 -1.26 
114 
 
rno-miR-204* 1.41 1.60 2.80 1.27 rno-miR-503 -1.05 1.25 1.04 -1.00 
rno-miR-206 -1.44 -3.23 -1.55 -1.43 rno-miR-505 -1.27 -1.99 -2.47 -1.20 
rno-miR-207 -1.87 -1.14 -1.21 -1.26 rno-miR-542-3p -1.14 1.12 -1.06 -1.24 
rno-miR-20a -1.03 1.37 1.41 -1.03 rno-miR-551b -1.12 -1.39 -1.56 -1.16 
rno-miR-21 2.71 3.13 2.95 2.30 rno-miR-652 -1.00 -1.15 -1.10 -1.33 
rno-miR-21* -1.02 1.24 1.48 1.20 rno-miR-742 1.04 -1.17 -1.30 -1.15 
rno-miR-214 1.13 1.77 1.31 1.20 rno-miR-743b 1.10 1.07 1.17 1.04 
rno-miR-22 1.08 1.12 1.05 1.05 rno-miR-7a 1.63 2.36 1.91 1.24 
rno-miR-22* -1.26 -1.90 -2.01 -1.26 rno-miR-872* -1.04 -1.17 -1.42 -1.26 
rno-miR-221 2.21 3.77 5.17 2.10 rno-miR-9 -1.14 -1.36 -1.35 -1.04 
rno-miR-222 2.42 4.69 3.76 2.19 rno-miR-93 -1.14 1.10 1.10 -1.00 
rno-miR-223 4.68 6.53 7.13 2.62 rno-miR-98 1.05 -1.18 -1.35 -1.18 
rno-miR-23a 1.08 1.12 1.08 1.03 rno-miR-99a -1.27 -1.92 -1.16 -1.12 
rno-miR-23b -1.06 -1.08 -1.06 -1.08 rno-miR-99b -1.26 -1.43 -1.92 -1.47 
























Appendix 2  miRNA array data of infarcted untreated rats (MI), infarcted placebo-, 
GYY-, and PAG- treated rats vs. sham at 7 days after MI 






























rno-let-7d* -1.00 -1.10 -1.82 1.15 rno-miR-31 1.48 4.17 1.07 1.85 
rno-let-7d -1.17 -1.31 -1.02 -1.08 rno-miR-32 1.27 -1.00 1.50 1.05 
rno-let-7i 1.07 1.17 -1.22 -1.03 rno-miR-320 -1.00 1.19 -1.14 1.05 
rno-miR-100 -1.21 -1.21 -1.18 1.04 rno-miR-331 1.05 1.09 -1.33 1.35 
rno-miR-101a 1.89 -1.00 1.25 2.05 rno-miR-335 1.74 1.92 1.86 1.97 
rno-miR-106b -1.02 1.09 -1.16 1.17 rno-miR-338 1.22 -1.12 1.28 1.14 
rno-miR-10a-5p -1.00 -1.47 -1.47 -1.12 rno-miR-338* 1.30 2.71 1.36 1.16 
rno-miR-125b-3p 1.20 1.57 1.45 -1.14 rno-miR-339-5p -1.00 1.08 -1.26 1.36 
rno-miR-126* -1.14 -1.37 -1.17 -1.17 rno-miR-342-3p 1.06 1.06 -1.27 -1.35 
rno-miR-126 -1.04 1.06 1.03 1.01 rno-miR-34a 1.11 1.87 1.49 1.30 
rno-miR-130a 1.16 1.16 -1.08 1.16 rno-miR-361 1.23 1.18 1.12 1.23 
rno-miR-133a -1.00 -1.75 -1.01 -1.00 rno-miR-365 1.25 1.45 1.28 1.41 
rno-miR-138* -1.50 -1.92 -1.46 -1.79 rno-miR-378* -1.24 -1.96 -1.00 1.15 
rno-miR-140* 1.05 1.92 -1.15 -1.00 rno-miR-378 1.06 -1.56 -1.00 1.06 
rno-miR-140 1.41 2.38 1.50 1.21 rno-miR-423 1.31 1.20 1.31 1.27 
rno-miR-142-3p -1.21 1.48 1.20 -1.21 rno-miR-425 -1.04 1.45 -1.04 1.07 
rno-miR-142-5p -1.00 1.30 1.11 -1.18 rno-miR-451 -2.04 -1.28 -1.24 -2.04 
rno-miR-143 -1.00 -1.00 -1.00 -1.00 rno-miR-487b -1.55 -1.60 -1.40 -1.64 
rno-miR-144 -1.56 -1.64 -1.05 -3.11 rno-miR-494 1.53 1.62 1.62 1.32 
rno-miR-145 -1.13 -1.41 1.13 -1.02 rno-miR-497 1.17 1.52 1.52 1.19 
rno-miR-146a -1.03 1.17 -1.03 1.07 rno-miR-499 -1.16 -2.36 -1.16 -1.11 
rno-miR-146b -1.07 1.16 -1.00 1.02 rno-miR-532-5p -1.00 1.18 1.02 1.18 
rno-miR-148b-3p -1.13 -1.00 -1.49 -1.02 rno-miR-542-3p 1.26 1.30 1.11 1.11 
rno-miR-150 -1.21 -2.42 -1.44 -1.36 rno-miR-542-5p 1.17 1.35 -1.23 1.35 
rno-miR-151 1.01 -1.05 -1.41 1.01 rno-miR-551b -1.14 1.04 -1.20 -1.11 
rno-miR-152 1.07 1.50 -1.33 1.01 rno-miR-652 -1.36 -1.07 -1.19 -1.12 
rno-miR-15b -1.02 1.67 1.02 -1.02 rno-miR-7a -1.07 1.14 1.21 -1.00 
rno-miR-181a 1.32 1.18 1.75 1.18 rno-miR-9 -1.37 -2.60 -2.06 -1.99 
rno-miR-181d 1.09 -1.60 1.30 -1.16 rno-miR-93 1.22 1.46 1.17 1.22 
rno-miR-184 -1.07 -1.04 -1.03 -1.20 rno-miR-98 -1.00 -1.00 -1.13 1.07 
rno-miR-185 1.09 -1.42 -1.25 1.06 rno-miR-99a -1.10 -1.18 -1.10 -1.10 
rno-miR-186 1.04 -1.02 -1.23 1.07 rno-miR-99b* 1.05 -1.02 -1.02 -1.06 
rno-miR-190 -1.06 -1.28 -1.24 1.19 rno-miR-99b 1.03 -1.00 -1.28 1.14 
rno-miR-191 -1.07 -1.10 -1.54 -1.10 rno-let-7a -1.06 1.08 -1.22 -1.06 
rno-miR-193 1.56 1.60 1.37 1.40 rno-miR-101b 1.03 -1.22 -1.04 1.08 
rno-miR-195 1.21 1.55 -1.00 1.21 rno-miR-107 1.21 1.13 1.55 1.24 
rno-miR-196a* -1.56 -2.82 -1.19 -3.92 rno-miR-129* -1.35 -1.81 -1.72 -1.62 
rno-miR-199a-3p 1.21 3.05 1.69 1.49 rno-miR-133b 1.26 -2.23 -1.00 1.11 
rno-miR-19a 1.12 1.26 1.59 1.07 rno-miR-17 1.02 1.32 1.12 1.02 
rno-miR-19b 1.09 -1.05 1.63 -1.10 rno-miR-181b 1.27 1.55 1.48 1.32 
rno-miR-203 -1.43 -1.49 -1.36 -1.61 rno-miR-199a-5p -1.00 2.13 1.28 1.10 
rno-miR-206 -1.30 -4.84 -1.07 -1.33 rno-miR-207 -1.15 -1.00 -1.00 -1.10 
rno-miR-208 1.00 -1.15 1.00 1.00 rno-miR-20a 1.06 1.10 1.04 1.06 
rno-miR-21 -1.01 1.05 -1.01 1.03 rno-miR-21* 1.18 1.70 1.26 1.15 
rno-miR-214 1.84 2.51 1.19 2.01 rno-miR-23b 1.07 1.36 1.31 1.07 
rno-miR-22* -1.16 -1.81 -1.34 -1.21 rno-miR-28 -1.14 -1.14 -1.29 -1.14 
rno-miR-22 -1.03 1.02 -1.03 -1.00 rno-miR-290 -1.46 1.04 -1.42 -1.28 
rno-miR-221 1.31 2.64 1.95 1.30 rno-miR-291a-3p -1.67 -1.96 -1.51 -1.80 
rno-miR-222 1.11 2.08 1.09 1.39 rno-miR-300-5p -1.08 -1.14 -1.11 -1.05 
rno-miR-223 -1.17 1.73 1.22 1.03 rno-miR-30b-3p -1.04 -1.04 -1.11 1.35 
rno-miR-24 1.09 1.07 1.10 -1.00 rno-miR-322 1.32 -1.03 1.24 1.32 
rno-miR-24-1* 1.02 -1.27 -1.27 1.06 rno-miR-325-3p -1.37 -1.91 -1.43 -1.43 
rno-miR-24-2* -1.03 -1.12 -1.08 -1.03 rno-miR-329 -1.15 -1.74 -1.01 -1.09 
rno-miR-25 1.37 1.68 2.04 1.42 rno-miR-34b 1.09 2.20 1.09 1.19 
rno-miR-26a -1.00 -1.03 -1.09 -1.05 rno-miR-34c* -1.35 -1.78 1.12 -1.39 
rno-miR-26b -1.00 -1.00 -1.00 -1.00 rno-miR-350 -1.13 -1.24 -1.31 -1.09 
rno-miR-27a 1.61 -1.05 2.01 1.37 rno-miR-351 -1.06 -1.03 -1.12 -1.12 
rno-miR-27b 1.18 1.09 2.16 1.07 rno-miR-434 -1.10 -1.47 1.12 -2.21 
rno-miR-29a* 1.12 -1.04 1.04 1.32 rno-miR-500 -1.08 1.49 -1.38 1.12 
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rno-miR-29a -1.00 1.04 1.02 -1.00 rno-miR-503 -1.00 1.08 -1.23 -1.07 
rno-miR-29b -1.25 -1.70 -1.25 -1.46 rno-miR-674-3p 1.33 1.66 -1.00 1.33 
rno-miR-29c -1.07 -1.50 -1.19 -1.00 rno-miR-872* -1.23 -1.00 -1.23 1.03 
rno-miR-301a 1.20 1.17 1.14 1.28 rno-miR-1 1.00 -1.02 1.00 1.00 
rno-miR-30a* -1.41 -3.94 1.04 -1.20 rno-miR-204* -1.18 1.22 1.02 -1.46 
rno-miR-30a -1.00 1.00 -1.00 -1.00 rno-miR-336 -1.33 -3.47 -1.40 -2.22 
rno-miR-30c 1.00 -1.02 1.00 1.00 rno-miR-347 1.20 -1.22 1.06 -1.22 
rno-miR-30c-1* -1.19 -2.83 -1.73 -1.03 rno-miR-352 -1.17 -1.08 1.15 -1.03 
rno-miR-30d -1.28 -2.01 -1.41 -1.11 rno-miR-382* 1.04 -1.36 1.42 -1.07 
rno-miR-30e* 1.15 -1.69 1.08 1.21 rno-miR-466c -1.00 1.18 1.18 1.10 
rno-miR-30e 1.08 -2.07 1.05 -1.00 rno-miR-664 1.21 1.51 -1.15 1.11 
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